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Enzymatic oxidoreductions are very important biotransformations for efficient 
asymmetric synthesis, especially for the production of enantiopure compounds 
in pharmaceutical industry. The aim of this thesis is to develop novel and 
efficient biocatalytic systems for oxidoreductions in pharmaceutical synthesis.  
In this thesis, biocatalytic system for bioreduction with efficient recycling of 
NADPH was developed by coupling permeabilized microorganisms. Coupling 
of permeabilized cells of Bacillus pumilus Phe-C3 containing an NADPH-
dependent ketoreductase and E. coli recombinant expressing GDH as novel 
biocatalytic system allowed for the enantioselective reduction of ethyl 3-keto-
4, 4, 4-triflurobutyrate with efficient recycling of NADPH:  a total turnover 
number (TTN) of 4200 was achieved by using E. coli BL21 (pGDH1) as the 
cofactor-regenerating microorganism with the initial addition of 0.005 mM 
NADP+. In long-term stability test, 50.5 mM of (R)-ethyl 3-hydroxy-4, 4, 4-
triflurobutyrate was obtained in 95% ee and 84% conversion with an overall 
TTN of 3400. Thus, a practical method for (R)-ethyl 3-hydroxy-4, 4, 4-
triflurobutyrate preparation was developed, and its principle is generally 
applicable to other microbial reductions with cofactor recycling. 
In this thesis, a recombinant Escherichia coli expressing P450pyr 
monooxygenase of Sphingomonas sp. HXN-200 was developed as a useful 
biocatalyst for regio- and stereo-selective hydroxylation, with no side 
reactions and easy cell growth. Biohydroxylation of N-benzyl pyrrolidine-2-
one with the resting cells gave (S)-N-benzyl-4-hydroxypyrrolidin-2-one in 
>99% ee and 10.8 mM, a 2.6 times increase of product concentration in 
X 
 
comparison with the wild-type strain. Moreover, hydroxylation of (-)-!-pinene 
with the recombinant E. coli cells showed excellent regio- and stereo-
selectivity and gave (1R)-trans-pinocarveol in 82% yield and 4.1 mM, which 
is over 200 times higher than that obtained with the best biocatalytic system 
known thus far. The recombinant strain was also able to hydroxylate other 
types of substrates with unique selectivity: biohydroxylation of norbornane 
gave exo-norbornaeol, with exo/endo selectivity of 95%; tetralin and 6-
methoxy-tetralin were hydroxylated at the non-activated 2-position, for the 
first time, with regioselectivities of 83-84%. 
In this thesis, the novel concept of utilizing tandem biocatalysts system for 
selective sequential oxidation-oxidation was first time proven by coupling 
whole-cell biocatalyst P. monteilii TA-5 containing monooxygenase with a 
commercially available enzyme Lactobacillus kefir alcohol dehydrogenase 
(LKADH), and using tetralin as substrate. Moreover, “coupled substrate” 
acetone and small amount of NADP+ were added for simultaneously cofactor 
recycling. By coupling 10+5 g cdw/L of P. monteilii TA-5 with 3 g protein/L 
LKADH, 6 mM tetralin was completely converted within 30 h. At the end 
point, pure 1-tetralone was produced in 5.25 mM with 87.5% yield, 99% 
regioselectivity, and a TTN of 2200 for NADP+ recycling. An increased TTN 
of 4100 was achieved by lowering initial amount of NADP+ to 0.001 mM. 
Indan with similar chemical structure to tetralin was also examined for the 
same sequential oxidations. The novel concept was also proved by sequential 
oxidation-oxidation of N-benzyl-piperidine to 1-benzyl-4-piperidone via 1-
benzyl-4-hydroxy-piperidine with two different biocatalysts. While E. coli 
(P450pyr) selectively hydroxylated non-activated methylene group of N-
XI 
 
benzyl-piperidine at 4-position, E. coli (RDR) further oxidized the C-H bond 
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ITPG                           Isopropyl !-D-Thiogalactopyranoside 
BSA                            Bovine Serum Albumin 
CFE                            Cell-free Extract 
MCS                           Multiple Cloning Site 
LB                              Luria-Bertani 
PCR                            Polymerase Chain Reaction 
SDS-PAGE                Sodium Dodecyl Sulfate-Polyacrylamide Gel  
                                   Electrophoresis 
 
KP                              Potassium Phosphate 
BA                              Benzyl Alcohol 
PA                              1-Phenylethanol 
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1.1 Background  
 
1.1.1 General applications of biocatalysis in pharmaceutical industry 
 
Biocatalysis has merged as an important tool in organic synthesis, especially 
in pharmaceutical industry. The main application of biocatalysis in 
pharmaceutical synthesis is to utilize its high selectivity to produce chiral 
compounds with high purity, which is usually difficult to achieve by 
traditional chemistry. In the past decade, the worldwide market for chiral fine 
chemicals has been increasing very fast with a growth rate of ca. 12% annually. 
According to the statistics of world chiral technology from Frost and Sullivan 
(Figure 1.1), the world annual market for chiral molecules was about 7 billion 
in 2002 US$, and biosynthesis accounted for 10% of world production of 
chiral chemicals. However, by the end of 2009, it rose to 22%, and the 
revenues for chiral technologies amounted to 14.9 billion US$.1 
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1.1.2 Cofactor recycling in biocatalytic oxidoreductions 
 
Biocatalytic oxidoreductions are important reactions in biosynthesis for chiral 
compounds.2-6 However, these reactions often need stoichiometric amount of 
the expensive cofactor NAD(P)H or NAD(P)+, which need to be efficiently 
recycled during the reaction for practical application.7-14 Enzymatic cofactor 
recycling can be realized by “coupled substrates”and “coupled enzymes” 
approaches (Fig.1.2). The latter is more general and utilizes the first enzyme 
for the desired biotransformation and the second one for cofactor recycling. In 
this approach, the cofactor regenerating biocatalyst is either isolated enzyme 
or whole cell containing necessary enzyme.15-23 While approaches based on 
isolated enzymes16-19,23 are expensive, less stable, approaches based on whole 
cells20-22 depend on the amount of available intracellular cofactor which may 

















   (ADH)
Enzyme B
Cosubstrate Coproduct
(a)          Coupled substrate (b)               Coupled enzyme
 
Figure 1.2. Substrate-coupled and enzyme-coupled approaches for NAD(P)H recycling. 
 
1.1.3 Regio- and stereo-selective biohydroxylation  
 
Regio- and stereo-selective hydroxylation, especially the hydroxylation at 




However, this type of transformations remains as a great challenge in classical 
chemistry. On the other hand, hydroxylation can be achieved by using an 
enzyme such as a monooxygenase which catalyzes the insertion of one O atom 
of molecular oxygen into a specific C-H bond (Fig.1.3). In addition to the high 
regio- and stereo-selectivity, biohydroxylation utilizes molecule oxygen as 
oxidant, thus being an ideal tool for green oxidation and sustainable chemical 
synthesis. Although many cytochrome P450 monooxygenases25-44 have been 
identified with the ability to catalyze regio- and stereo-selective hydroxylation, 
it is still difficult to obtain appropriate monooxygenase with desired substrate 
specificity and high selectivity and to construct active recombinant 
biocatalysts via genetic engineering of P450 monooxygenase thus far, possibly 
due to the particular complicacy of P450 enzyme and system.  
    
R H + O2 + +H+ NAD(P)H
Monooxygenase R OH + NAD(P)+ + H2O
 
Figure  1.3. Selective biohydroxylation catalyzed by monooxygenase. 
 
1.1.4 Tandem biocatalysis  
 
Tandem biocatalysis with multiple biocatalysts in one pot enables multi-step 
sequential reactions in the same mild conditions, thus avoiding the time-
consuming, yield-decreasing, and waste-producing isolation and purification 
of intermediates (Fig.1.4). Tandem biocatalysis is regarded as an important 
direction for sustainable chemical and pharmaceutical synthesis, and gaining 
more and more attention.45-53 Although in nature, it is quite common that a 
single microorganism that contains multiple enzymes can uptake and 
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metabolize nature compound such as glucose,54-59 it is not easy to find and 
array appropriate multiple biocatalysts to carry out sequential bioconversions, 
especially for efficient oxidoreductions. In terms of tandem biocatalysts 
systems for enzymatic sequential reactions, only two deracemization examples 
of sequential oxidation-reduction for deracemization have been reported thus 
far.60-62 In terms of enzymatic sequential oxidation-oxidation with tandem 
biocatalysts systems, due to the complicacy of its electron transfer system and 



















 Figure 1.4. Comparison of traditional vs. tandem catalysis. 
 
1.2 Objective and Approach 
 
The main purpose of this thesis is to develop novel and efficient biocatalytic 
systems for oxidoreductions in pharmaceutical synthesis. More specifically: 
1) We aim to develop an efficient bioreduction system with cofactor 
recycling by coupling two permeabilized microogransims.     
  Traditional catalysis                                       Tandem catalysis 
Traditional catalysis                                  
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Previously, we developed a novel method for efficient bioreduction 
with cofactor recycling by coupling two permeabilized micro-
organisms, one containing keto-reductase, while the other containing 
glucose dehydrogenase (GDH).63 However, the total turnover number 
(TTN) for cofactor recycling and final product concentration were not 
high enough for practical application. The main reason is the relative 
low activity of the whole cell biocatalyst for cofactor recycling. We 
want to improve the TTN for cofactor recycling and final product 
concentration in this bioreduction system by enhancing the activity of 
the cofactor regenerating strain. Because nicotinamide cofactor 
normally has a half-life time about 24 h in reaction system, by 
increasing the activity of cofactor regenerating strain, more products 
could be produced before the cofactor completely decomposes, thus 
leading to higher TTN for cofactor recycling. Firstly, we construct a 
recombinant strain for cofactor recycling with improved activity by 
choosing suitable plasmid, suitable host cell, and expression 
optimization. Then, we permeabilize the new cofactor recycling strain 
and couple it with permeabilized bioredcution strain in order to achieve 
higher TTN and increased final product concentration. 
2) We aim to engineer a recombinant E. coli strain expressing P450pyr 
monooxygenase with high hydroxylation activity, no side reaction, and 
easy growth on non-flammable substrate, and then employ this 
recombinant strain for regio- and stereo-selective hydroxylation. 
Previously, we discovered Sphingomonas sp. HXN-200 containing a 
P450pyr monooxygenase as a powerful biohydroxylation catalyst with 
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unique substrate specificity and range as well as high selectivity.64 The 
wild-type strain was shown to be the best catalyst known thus far for 
the hydroxylation of a range of alicyclic substrates.65-68 Later, a 
Pseudomonas putida strain expressing P450pyr monooxygenase was 
constructed.69 However, the hydroxylation activity of the P. putida 
recombinant strain was rather low. Moreover, both the wild-type strain 
and the P. putida recombinant need to grow on n-octane which is a 
flammable and relatively expensive substrate, thus being a technical 
challenge in large-scale application. By the means of choosing suitable 
plasmid, suitable host cell, construction strategy, and expression 
optimization, we construct a new E. coli recombinant strain which is 
able to grow easily in LB media, shows elevated hydroxylation activity, 
and gives higher product concentration compared to either our wild-
type strain Sphingomonas sp. HXN-200 or the best biocatalyst know 
thus far. Final product concentration is one of the key critieria 
commonly used to evaluate a chemical process in pharmaceutical 
industry.  
3) We aim to develop novel tandem biocatalysis as the first example for 
selective sequential oxidations of methylene group into ketone by the 
use of a monooxygenase and an alcohol dehydrogenase (ADH) in one 
pot.  
Selective oxidation of methylene group (C-H bonds) into ketone is a 
useful synthetic method to generate many crucial chemical and 
pharmaceutical compounds. However, methylene groups, abundant in 
chemical structures, are the most challenging chemical groups to be 
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selectively functionalized, since they are inert to most chemical 
reagents. Thus far, the selective oxidation of methylene groups into 
ketone still poses a great challenge to traditional chemistry.70-79 
Furthermore, it has remained impossible to oxidize non-activated C-H 
into C=O with high selectivity.80-83 Tandem biocatalysis for selective 
sequential oxidations of methylene group into ketone by the use of a 
monooxygenase and an alcohol dehydrogenase (ADH) in one pot 
might be a possible alternative. In nature, it is quite common that 
microbial cells containing multiple enzymes can uptake and metabolize 
nature compound via sequential bioconversions. However, it is not 
easy to find and array appropriate multiple biocatalysts to carry out 
sequential biocatalysis with non-natural substance to achieve full 
conversion. To date, only scarce examples have been reported for 
sequential transformations with tandem biocatalysis in organic 
synthesis, and there is no tandem biocatalysts system for sequential 
oxidations has been reported yet. It is difficult in both concept and 
practice. Enzymatic oxidations are quite complicated, involving 
electron transfer, varied mechanisms, etc, and it is difficult to 
efficiently find and arrange necessary biocatalysts for tandem 
biooxidations. We look for suitable biocatalysts from strain stock in 
our lab, as well as commercially available enzymes, and then fine-tune 








After this introduction, an overview of biocatalysis is provided, especially 
oxidoreductions in pharmaceutical synthesis. In Chapter 3, the bioreduction 
with efficient recycling of NADPH by coupled permeabilized microorganism 
is described. The regio- and stereo-selective biohydroxylations with a 
recombinant Escherichia coli expressing P450pyr monooxygenase of 
Sphingomonas sp. HXN-200 is discussed in the following Chapter. In Chapter 
5, the green and selective transformation of methylene to ketone via tandem 
biooxidations in one pot is demonstrated. Chapter 6 concludes the whole thesis 











































































2.1 Overview of Biocatalysis in Organic Synthesis 
 
Brewing, with a history about 6,000 years, is one of the oldest biocatalyses 
known to humans. Only in recent 100 years, biocatalysis is employed for the 
production of non-natural organic compounds, either with isolated enzyme or 
with whole cells. For the past 30 years, biocatalysis is increasingly applied to 
the synthesis of fine chemicals, especially in pharmaceutical industry. The 
growing emphasis on green and sustainable processes makes biocatalysis a 
more and more valuable alternative to traditional chemistry in chemical 
synthesis.84  
. 
2.1.1 Advantages of biocatalysis 
 
Biocatalysis has plenty of advantages: biocatalysis is usually highly selective, 
including chemo-, regio-, and stereo-selectivity; biocatalysis has mild 
operation conditions, such as room temperature and neutral pH; enzymes are 
non-toxic catalysts; multiple biocatalyses can be performed in one pot, thus 
allowing cascade reactions which avoid the time-consuming, yield-reducing, 
and waste-producing purification of intermediate; enzymes are efficient 
catalysts, and the rates of biocatalysis are much higher than their chemical 
counterparts by some orders of magnitude; biocatalysis usually generates 
minimal undesired side-reactions such as rearrangement, decomposition, 
isomerization and racemization due to their mild operation conditions; 
enzymes can catalyze a broad range of reactions, including the selective 
conversion at non-activated sites in a substrate which is very difficult for 
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traditional chemistry; enzymes are not restricted to their natural substrates, 
many enzymes exhibit a high substrate tolerance to non-natural substances; 
enzymes can also work in an non-aqueous environment, and some enzymes 
can catalyze the reaction in organic solvent or in biphasic system to improve 
substrate and product solubility.85,86 
 
2.1.1.1 High selectivity (chemo-, regio- and stereo-selectivity) 
 
The primary reason for using biocatalysis in organic synthesis is to utilize the 








Grape (Vitis vinifera L.)
 
 
Scheme 2.1 Chemoselective bioreduction of aromatic nitro group to hydroxylamine. 
 
The chemoselectivity of enzymes means that they can selectively act on a 
single type of functional group while in the presence of others. For instance, 
cells from a grape (Vitis vinifera L.) reduced aromatic nitro compound 4-nitro-
substituted naphthalimide to the corresponding hydroxylamine with 100% 
chemoselectivity (Scheme 2.1). In this case, only nitro group of the substrate 
was selectively reduced, while carbonyl groups survived. Furthermore, the 
reaction stopped at the stage of hydroxylamine, no further reduced product 
amine was examined.88 
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The regioselectivity of enzymes means that they may be able to distinguish 
between functional groups which are chemically situated in different regions, 
due to their complex three-dimensional structure. For example, Sphingomonas 
sp. HXN-200 selectively hydroxylated N-benzyl-piperidin-2-one at 4 position 
to produce 4-hydroxypiperidion-2-one with 99.9% regioselectivity, while kept 










Scheme 2.2 Regioselective biohydroxylation of N-benzyl-piperidin-2-one to 4-
hydroxypiperidion-2-one. 
 
The stereoselectivity of enzymes means that they can catalyze the reaction in 
which one enantiomer is formed in preference to the other. This is because 
enzymes are chiral catalysts since almost all of them are made from L-amino 
acids, and their specificity can be exploited for selective and asymmetric 
conversions. For example, tetralin was selectively hydroxylated with resting 
cells of Pseudomonas monteilii TA-5, giving the optically active product (R)-









Due to its exquisite chemo-, regio-, and stereo-selective properties, 
biocatalysis is widely used for selective transformation, especially for those, 
which are not easy to be achieved by classical organic chemistry.  
 
2.1.1.2 Environmentally benign catalysis 
 
Most biocatalysis can be performed in an environmentally benign manner, e.g., 
operation in water at ambient temperature and neutral pH, environmentally 
compatible and biodegradable catalyst (an enzyme) derived from renewable 
raw materials, capability to metabolize natural substrates (renewable raw 
materials) to produce useful products, avoiding the use of large amount 
organic solvent and toxic metal catalysts, no need for high pressure and 
extreme conditions, thereby minimizing the hazardous substances involved, 
and saving energy normally required for processing. 
Due to its environmentally benign feature, biocatalysis is regarded as a 
promising way to achieve green chemistry goals. Green catalytic synthesis that 
meets increasingly stringent environmental requirements is greatly demanded 
in pharmaceutical and chemical industries. Green chemistry, also called 
sustainable chemistry, can be conveniently defined as: the efficient utilization 
of (preferably renewable) raw materials, elimination of waste and avoiding the 
use of toxic and/or hazardous reagents and solvents in the manufacture and 
application of chemical products. 45,90 
Furthermore, the use of enzymes generally circumvents the need for the 
functional group activation and protection often required in traditional organic 
syntheses, affording more environmentally and economically attractive 
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processes with fewer steps and, hence, less waste. This is clearly illustrated by 
the remarkable transition of deacylation of penicillin G into 6-
aminopenicillanic acid (6-APA) from multiple-step classical chemical 
synthesis (Scheme 2.4) to biotransformation (Scheme 2.5).91 The one-step 
enzymatic cleavage of penicillin G was carried out in water rather than in 
halogenated solvent PCl5 at -40 °C with multiple-step reactions, and afforded 
6-APA in excellent yield.92,93 It is estimated that at least 16,000 tones of 6-





























































2.1.2 General applications of biocatalysis in organic synthesis 
 
Biocatalysis has emerged as an important tool in organic synthesis. A large 
number of fine chemicals have been produced by the means of biocatalysis, 








































  Nicotinamide                  Acrylamide          1,5-Dimethyl-2-piperidone
(S)-tert-Leucine                  Ephedrine                       Aspartame
              Amoxicillin                                                    Cephalexin
 
Figure 2.1. Fine chemicals that are produced by biocatalysis. 
 
Chiral compounds account for a large part of pharmaceutical products. In 2000, 
35% of pharmaceutical intermediates were chiral and this number is expected 
to increase to 70% by the end of 2010.95,96 It has been known for the last 
decades that different stereoisomers frequently differ in terms of their 
biological activity and pharmacokinetic profiles, and the use of such mixtures 
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or opposite enantiomer may contribute to the adverse effects of the drug. For a 
striking example, the (R)-sopromidine is an agonist at H2-receptors, while the 
(S)-enantiomer is an antagonist; the racemate exhibits the properties of a 
partial agonist on guinea pig atrium preparation (Figure 2.2).97 Although the 
major regulatory authorities including Food and Drug Administration of the 
United States of America (FDA) do not force the submission of single enantiomer 
drugs, they do encourage it by requiring additional information on the 
pharmacology effect of racemic candidates. As a result, in recent years, the 
percentage of single isomer drugs approved by FDA kept increasing. 
 














   

























Figure 2.3. Atorvastation (Lipitor®): inhibitor of HMG-CoA reductase. 
Agonist at H2-receptors 





Biocatalytic production of enantiopure compounds can be divided into two 
different manners: kinetic resolution of a racemic mixture and asymmetric 
synthesis.  
Biocatalysis plays important role in the manufacture of pharmaceuticals, 
where selective reactions are very crucial. Many important pharmaceutical 
intermediates and products synthesized by biocatalysis have been reported.98,99 
For example, Lipitor developed by Pfizer is one of the best-selling drugs in the 
world (Figure 2.3), and its key intermediate hydroxynitrile was produced by 
biocatalysis. Reduction step gave exquisite ee >99.9 % and cyanation step 
maintained stereochemistry completely (Scheme 2.6).100 This process has 












Scheme 2.6 Manufacture of pharmaceutical intermediate Hydroxynitrile (ee > 99.9%). 
 
2.1.2.1 Biocatalytic kinetic resolution of a racemic mixture 
 
In biocatalytic kinetic resolution of a racemic mixture, one of the enantiomers 
can be converted at a higher rate than the other enantiomer. For example, a 
dehalogenase from Pseudomonas putida catalyzed the (R)-isomer of racemic 
2-chloropropanoic acid into lactic acid, while the (S)-2-chloropropanoic acid 
was unreacted, and then isolated from the reaction mixture (Scheme 2.7).101 
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The biotransformation was brought to full-scale manufacture in 1991, and 


















Scheme 2.7 Kinetic resolution of 2-chloropropanoic acid. 
 
In theory, the maximum yield of such kinetic resolutions is 50%, since both 
enantiomers are equal in the racemic mixtures. However, if the two 
enantiomeric substrates can continuously racemize during the resolution, then 
all substrate may be converted into enantiopure product. This is called 
dynamic kinetic resolution (DKR). For example, lipase was used as the 
biocatalyst in the enantioselective hydrolysis of (S)-naproxen thioester from 
racemic naproxen thioester, in which trioctylamine was added to perform in 



































2.1.2.2 Biocatalytic asymmetric synthesis 
 
Enzyme, as an enantiopure substance, can introduce chirality into non-chiral 
substrate in enantioselective way. For example, yeast Saccharomyces 
cerevisiae selectively reduced !-chloroacetoacetic acid octyl ester by addition 
of hydrogen on a carbonyl group, to give the intermediate (R)-!-chloro-"-
hydroxybutanoic acid octyl ester (Scheme 2.9) for L-carnitine synthesis.103 
The high selectivity of the enzyme-catalyzed reaction results in the formation 
of only one enantiomer of the product, and this biosynthetic process is used to 









!--chloroacetoacetic acid octyl ester (R)-!-chloro-"-hydroxybutanoic acid octyl ester  
  




Enzymes are proteins with catalytic functions, thus being able to initiate or 
increase the rate of a biochemical reaction. They could be used as isolated 






2.2.1 Classification of enzymes 
 
Table 2.1 Classification of enzymes 
 
Enzyme Class Reaction Catalyzed Enzyme examples  
1. 
Oxidoreductases 
To catalyze oxidation/reduction reactions; 
transfer of H and O atoms or electrons from 





Transfer of a functional group from one 
substance to another. The group may be 











Non-hydrolytic addition or removal of 
groups from substrates. C-C, C-N, C-O or 





Intramolecule rearrangement, i.e. 






Join together two molecules by synthesis of 
new C-O, C-S, C-N or C-C bonds with 
simultaneous breakdown of ATP 
Synthetase  
 
The enzymes that have been exploited for organic synthesis, as well as the 
type of reaction catalyzed, are summarized in Table 2.1.86 The importance of 
practical applications for organic synthesis is not all evenly distributed among 
different enzymes. Among all these enzymes, hydrolases and oxidoreductases 




2.2.2 Exploitation of enzymes 
 
New or improved biocatalysts can be obtained in several different ways-
screening available natural sources, genetic engineering and protein 
engineering of known enzymes. In 2006, over 3,000 enzymes have been 
recognized by the International Union of Biochemistry (IUB), and this number 
may be greatly augmented in the wake of genomic and proteomic research.86 
 
2.2.2.1 Screening of new microorganisms 
 
Screening of a broad variety of microorganisms represents the traditional 
method used to discover new enzymes. Microorganisms are of particular 
interest because of their short generation time and large diversity of metabolic 
pathways and enzymes.  
In vivo screening of microorganisms is often used for the discovery of new 
enzyme, especially for cofactor dependent multi-component enzyme.105,106 To 
avoid random screening of a large number of microorganisms, pre-selection 
are usually done on microorganisms which possibly contain the desired 
enzymes based on their degradation ability. Miniaturized screening system 
allows the parallel inoculation, growth, and bioconversion of microorganisms 
on microtiter plates, thus greatly improving the screening efficiency. For 
example, F. Lie et al. collected and isolated a set of 22 toluene- and 
ethylbenzene-degrading strains from the sediment, and topsoils in Singapore. 
Those strains were screened for the enantioselective benzylic hydroxylation of 
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indan and tetralin, and Pseudomonas monteilii TA-5 was discovered as an 
active and selective biocatalyst for such hydroxylation (Fig.2.4).89 
 
 






Figure 2.4. Screening of efficient biocatalysts for enantioselective benzylic hydroxylation. 
 
2.2.2.2 Genetic engineering of recombinant strains for more efficient 
biocatalysts 
 
In general, microorganisms isolated from nature only can produce the desired 
enzyme at a low level, with low activity, or even with low selectivity, which 
cannot provide an economical production process, thus a modification of the 
enzyme is needed.  
Genetic engineering or recombinant DNA technology is developed by which 
the genes encoding the desired enzyme could be over-expressed in well-
understood host microorganisms. The resulting engineered strains express the 
desired enzyme at an elevated level, thus providing a more economical 
production process. Moreover, the engineered strains can also avoid side 
 n = 1
 n = 2
n n
OH
Pseudomonas monteilii  TA-5
99% ee, 65% yield
99% ee, 63% yield
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reactions which the original microorganism may suffer, since the genes coding 
for the enzyme catalyzing unwanted reaction are not transferred into the new 
host cells. K. J. Xiang et al. engineered a recombinant Escherichia coli (E. coli) 
strain over-expressing glycerol dehydrogenase (GldA) (Fig.2.5), and the 
recombinant strain demonstrated much higher catalytic activity compared to 












Figure 2.5. Construction of recombinant strain. 
 












Original  Recombinant 
gldA E. coli genome gldA Amp’ 
Ligase 
BamH # and Xho#  
Amp’ 
Recombinant Plasmid  
pET-21b 
Expression 




Host E. coli cell  
gldA 
Amp’ 
Only gldA’ recombinants 
can survive 
LB Plate (Amp’) 
and Xho#  
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2.2.2.3 Protein engineering for creating new biocatalysts with improved 
catalytic performance 
 
The general strategies for protein engineering are random mutagenesis, site-
directed mutagenesis and directed evolution. 
Random mutagenesis or site-directed mutagenesis, which could randomly or 
directionally replace one or a few amino acid residues in the gene sequence, 
has led to the development of enzyme variants with a better biocatalytic 
performance. However, such kind of mutagenesis is not always effective, and 




Figure 2.7. Directed evolution. 
 
Directed evolution mimics natural evolution and generally produces superior 
results than simple random mutagenesis or site-directed mutagenesis. In this 
method, random mutagenesis is first applied to a protein, and a selection 






Add new diversity 







of mutation and selection are then applied on the basis of backbone selected in 
the last round. DNA shuffling technology enables the mixing and matching 
pieces of successful variants in order to produce better results (Fig.2.7).108 
High throughput (HTP) screening methods and robotic equipments speed up 
the screening process, allowing many rounds evolution in a short period. 
Tremendous progress in genomics and bioinformatics also facilitates directed 
evolution.109 
 
Table 2.2 Alkane oxidation by wild-type P450BM-3 and its 139-3 variant 
Substrate 
Maximum turnover rate Product distribution (%) 
Wild-type 139-3 Variant Product Wild-type 139-3 Variant 

















cyclohexane 151 3910 cyclohexanol 100 100 
n-butane 17 1830 2-butanol n.d 100 
propane 15 860 2-propanol n.d 100 
 
Directed evolution, which enables the possible creation of designer catalysts, 
has particularly contributed significantly to elucidate enzyme structure and 
mechanism, improve enzyme activity, increase enzyme chemo-, regio- and 
stereo-selectivity, broaden their substrate specificity, increase solvent 
tolerance, increase thermo-stability, and overcome substrate or product 
inhibition. For example, Arnold et al. applied directed evolution to engineer 
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P450 BM-3 for alkane hydroxylation. A very active P450 BM-3 variant 139-3 




Oxidoreductase is a type of enzymes that catalyze the transfer of electrons 
from hydrogen or electron donor to hydrogen or electron acceptor, which leads 
to electron transfer, proton abstraction, hydrogen extraction, and hydride 
transfer or oxygen insertion. Oxidoreductase widely exists in microbes, plants 
and animals. Oxidoreductase can be classified into oxidases, peroxidases, 
oxygenases/ hydroxylases, and dehydrogenases/reductases according to the 
type of reactions they can catalyze. Oxidoreductase catalyzed 
biotransformations are very important for efficient asymmetric synthesis. They 
can catalyze both aliphatic and aromatic substrates; functionalize 
hydrocarbons by hydroxylation, sulfoxidation, epoxidation; carry out chemo-, 
regio- and stereo-selective reactions; create important intermediates and 




Reductases are good biocatalysts for asymmetric synthesis. NAD(P)H-
dependent dehydrogenases catalyzed enzymatic reductions are very useful 
reactions in asymmetric synthesis and industrial production of enantiopure 
synthons and pharmaceutical intermediates, such as hydroxy acids, amino 
acids, steroids, or alcohols from prochiral precursors. For example, they can 
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directly convert prochiral ketone to chiral alcohol with high enantioselectivity 
(Scheme 2.10).113 They also can catalyze the corresponding reverse reaction-












Scheme 2.10 Reactions catalyzed by NAD(P)-dependent dehydrogenases leading to chiral  
alcohols. 
 
The interconversion of a ketone to the corresponding alcohol and vice versa 
represents one of the most common redox-reactions in organic chemistry. 
Whereas traditional synthetic methods predominantly use toxic metals and 
expensive complex hydrides, biotransformations offer some significant 
advantages. They are highly selective, many problems of chemical reduction 
such as racemization can be avoided because of the mild enzymatic reaction 
condition, and many alcohol dehydrogenases (ADHs) accept a broad variety 
of ketones and ketoesters as substrates. 
ADHs are in generally subdivided into three groups: the medium-chain, zinc-
containing ADHs, represented by horse liver ADH; short-chain ADHs without 
any metal ion, represented by the Drosophila ADH; and the "iron-activated" 
long-chain ADHs with the ADH II from Zymomonas mobilis as the typical 
enzyme of this group.114 
 
2.3.1.1 Selective bioreduction of ketones 
 
Methods to produce chiral alcohols with ADHs are essentially described, 
especially using Horse liver alcohol dehydrogenase (HLADH), 
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Thermoanaerobium brockii alcohol dehydrogenase (TBADH), Lactobacillus 
kefir alcohol dehydrogenase (LKADH), Lactobacillus brevis alcohol 
dehydrogenase (LBADH), and Rhodococcus erythropolis alcohol 
dehydrogenase.  
NADP-dependent LKADH can reduce ketone to (R)-alcohols in high 
enantiomeric excess. Due to the broad substrate specificity of this enzyme, 
aromatic, cyclic, polycyclic as well as aliphatic ketones can be reduced. A 
simple method for the recycling of NADPH is given by the simultaneously 
coupled oxidation of isopropanol (IPA) by the same enzyme. For instance, 
reduction of 10 mM acetophenone with recycling of NADPH (0.2 mM) in the 
presence of isopropanol, 8.0 mM (R)-phenylethanol was produced in 1 h 
(Scheme 2.11).115 
 








Scheme 2.11 Selective bioreduction of acetophenone to (R)-phenylethanol. 
 
2.3.1.2 Selective oxidation of sec-alcohols 
 
ADHs also can catalyze the oxidation of sec-alcohols to ketone, while the 
availability of environmentally benign oxidation methods for the oxidation of 
sec-alcohols to the corresponding ketones still represents a significant problem 
for synthetic organic chemistry.  
B. Kosjek et al. demonstrated the selective oxidation of (S)-4-(p-
hydroxyphenyl)butan-2-ol (rhododendrol) into 4-(p-hydroxyphenyl)butan-2-
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one (raspberry ketone) by R. ruber ADH (Scheme 2.12). Biocatalytic 
oxidative kinetic resolution of racemic rhododendrol led to the production of 
raspberry ketone, as well as enantiopure (S)-rhododendrol in 98% ee. The 











raspberry ketone  
Scheme 2.12 Selective oxidation of (S)-rhododendrol into raspberry ketone. 
 
2.3.2 Monooxygenases  
 
Monooxygenases are also good biocatalysts for asymmetric synthesis. They 
can functionalize molecules such as hydrocarbon by inserting active O atoms, 
which are very difficult for conventional chemistry. For example, cytochrome 
P450, one of important monooxygenases, can catalyze selective carbon 
hydroxylation, heteroatom oxygenation, dealkylation, epoxidation, aromatic 
hydroxylation, reduction, and dehalogenation.117 Baeryer-Villiger 
monooxgenase (BVMO) is another important oxygenase, since it is able to 
catalyze the nucleophilic oxygenation of ketone. This enzymatic method is 
much more advantageous than the conventional chemical ways, which 




2.3.2.1 Selective biohydroxylation 
 
Regio- and stereo-selective hydroxylation, especially the hydroxylation at 
non-activated carbon atom, is a very useful reaction in organic chemistry. For 
example, it could be used in the chemical industry to activate alkanes, one of 
the least expensive and most abundant hydrocarbon resources. It could also be 
used in pharmaceutical industry to prepare chiral alcohols that are useful 
synthons or pharmaceutical intermediates. This transformation has received 
much attention over several decades, but it still remains as a significant 
challenge in classic chemistry. Some progress has achieved with metal 
catalysts. However, the regio- and stereo-selectivities of these chemical 
catalysts are generally very poor.  
Monooxygenases can catalyze the selective insertion of one O atom of 
molecular oxygen into a C-H bond, while reducing the second O atom into 
H2O with electrons from NADH or NADPH. Such biohydroxylation has 
several distinctive features: it is often highly regio- and stereo-selective; it 
uses oxygen as a cheap and non-toxic oxidant, thus being environmentally 
benign; and it is often highly efficient and could provide economically 
competitive process for practical synthesis. Biohydroxylations have been 
applied in organic synthesis, including the hydroxylation of steroids, terpenes, 
and some other alicyclic compounds.7 
Some monooxygenases, such as the soluble cytochrome P450 
monooxygenases, the soluble methane monooxygenase (sMMO), and the 
membrane-bound alkane hydroxylase (AlkB), have been extensively 
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investigated. The X-ray structures of several soluble bacterial P450s25-27 and 
sMMO hydroxylase (MMOH)28 are known.  This relatively complex 
hydroxylation system often requires a metal center: while P450 
monooxygenase contains heme iron, MMOH or AlkB has a non-heme iron 
center. Electron transfer from the reduced cofactors often requires additional 
proteins, such as a reductase MMOR in sMMO, a rubredoxin (AlkG) and 
rubredoxin reductase (AlkT) in the AlkB system, and a ferredoxin (Fdx) and a 
ferredoxin reductase (FdR) in P450cam (Figure 2.8). 29,105 
 
 
Figure 2.8. P450cam biohydroxylation system. 
 
Among all types of monooxygenases, cytochrome P450 monooxygenases are 
of great interest, due to their wide existence in nature and high diversity. Many 
P450 monooxygenases from wild-type strains were identified for 
biohydroxylations,30,31 and some of them, such as P450cam and P450BM-3, have 
been characterized,25-27 cloned and expressed,32-36 and engineered via directed 
evolution24,27-41 or protein engineering42-44 to improve the substrate range, 
activity, and regio- and stereo-selectivity. Thus far, it is still difficult to obtain 
appropriate P450 monooxygenase with desired substrate specificity and high 
selectivity and to construct active recombinant biocatalysts via genetic 
engineering of P450 monooxygenase, possibly due to the particular 








Sphingomonas sp. HXN-200 containing cytochrome P450pyr has been found 
to be a particularly promising hydroxylating system due to its high activity, 
regio- and stereo-selectivity and ease of use as a biocatalyst. Sphingomonas sp. 
HXN-200 was found to contain a soluble alkane monooxygenase and was 
shown to be the best catalyst known thus far for the hydroxylation of a range 
of alicyclic substrates such as N-substituted pyrrolidines,65 pyrrolidinones,66 
piperidines,67 piperidinones,68 and azetidines,67 with high activity and good to 
excellent regio- and stereo-selectivity (Scheme 2.13). Moreover, cells of 
Sphingomonas sp. HXN-200 can be easily prepared in large amounts and 
stored at -80oC for 2 years without any significant loss in activity after being 
thawed and resuspended. However, the wild-type strain needs to grow on n-
octane, which is a flammable and relatively expensive substrate, thus being a 












































Although oxidoreductases are very important for organic synthesis, only few 
oxidoreductases have been commercialized until now, because their 
biocatalytic systems are relatively complicated, and often require expensive 
cofactors. 
 
2.4 NAD(P)+ and NAD(P)H Recycling 
 
Enzymatic oxidoreductions catalyzed by oxidoreductases often require 
stoichiometric amount of cofactors. The most important cofactors involved in 
biocatalytic oxidations and reductions include flavine adenine dinucleotide 
(FAD) and flavine mononucleotide (FMN), adenosine triphosphate (ATP), 
nicotinamide adenine dinucleotide NAD+, and nicotinamide adenine 
dinucleotide phosphate NADP+.119 These cofactors act as transport metabolites, 
transporting hydrogen, oxygen or electrons on the one hand, or other atoms or 
molecules on the other, between different parallel reactions. 
Among these cofactors, some of them are firmly bound to the enzymes, such 
as FAD and FMN. By contrast, ATP, NAD and NADP mostly exist as soluble 
component of the enzyme. Statistically, almost one fifth of all enzymes 
registered at the International Union of Biochemistry require dissociable 
cofactors, as so-called ‘free cofactors’. AMP/ADP/ATP is required for 
biochemical energy transfer, and most reaction systems they are used in are 
too complex for economical applications in cell free systems. Thus, nearly no 
product of economic importance has emerged that requires these cofactors in 
cell free synthetic reactions so far. However, NAD+/NADH and 
NADP+/NADPH dependent oxidoreductions have been widely studied and 
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used in various fields, particularly for the production of various valuable 
enantiopure chiral compounds. 
 









































Figure 2.9. Structures of the cofactors NAD(P)+ and NAD(P)H. 
 
The pyridine nucleotide cofactors NAD(P)+ and NAD(P)H are essential 
components of cells, where they act as electron carriers or acceptors in 
reduction and oxidation reactions. The functions of them are related to unique 
structures of their molecules which combine several functional groups 
together (Fig.2.9). The nicotinamide moiety is the oxidation/reduction center. 
The remaining portion of the molecule is important for selective interactions 
with different enzymes. In nicotinamide adenine dinucleotide (NAD+), the left 
part is adenosine diphosphoribose, while in nicotinamide adenine dinucleotide 
phosphate (NADP+) it has an additional phosphate group esterified to the 2' 
hydroxyl of the adenine. Unlike other electron transfer centers such as Cu, 
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heme, and flavin, these molecules exist free in solution and function by 
binding to enzymes transiently during enzymatic oxidation and reduction. 
NAD(P)+ and NAD(P)H play an increasingly important role in biotechnology 
industry. They are used in various analytical, biomedical, and technological 
processes, where they take part in a wide range of oxidation-reduction 
reactions via pyridine-dependent dehydrogenases that lead to the synthesis of 
fine chemicals for the pharmaceutical and food industries. 
 
2.4.2 Reasons for NAD(P)+ and NAD(P)H recycling 
 
Table 2.3 Costs of NAD(P)+ and NAD(P)H 
Cofactor 
!/g 






NAD(P)+ and NAD(P)H are necessary for most biocatalytic oxidations and 
reductions. However, the high cost (Table 2.3)119 makes their stoichiometric 
application economically unfeasible. Thus, the recycling of cofactor is 
necessary in order to develop economically and industrially feasible process.  
In addition to reducing the cost of synthesis, cofactor recycling is also 
synthetically advantageous. Firstly, cofactor recycling can drive the reaction to 
completion by coupling substrate conversion leading to an equilibrium 
constant, which favors the product formation. Secondly, cofactor recycling can 
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simplify the reaction work-up, since it eliminates the need for stoichiometric 
quantities of cofactors.8 
 
2.4.3 Methods for NAD(P)+ and NAD(P)H recycling 
 
For a feasible cofactor recycling method, some basic criteria need to be met. 
First, all the chemicals and facilities, including enzymes, reagents and 
necessary equipments should be readily available, inexpensive, easily 
manipulated and stable under operation conditions. Furthermore, the recycling 
step should be kinetically and thermodynamically favorable. Last but not the 
least, none of the byproducts generated from recycling step should interfere 
with product isolation.  
In order to evaluate the effectiveness of a cofactor recycling process, the 
concept “total turnover number” (TTN) is typically introduced. It is defined as 
the total number of moles of product formed per mole of cofactor used during 
the course of a complete reaction.120 Generally, TTNs of 4,000-5,000 should 
be sufficient economically considering the value of product. 
In the past three decades, many research groups have been devoted to the 
development of cofactor recycling, and several recycling approaches have 
been investigated and used, including enzymatic method, electrochemical 







2.4.3.1 Enzymatic method 
 
Enzymatic methods for cofactor recycling are most widely studied by 
numerous research groups. Many enzymatic systems for nicotinamide cofactor 
recycling have been tested. The best methods are based on the use of formate, 
glucose, glucose-6-phosphate, or alcohols as reducing agents.15,126 The 
advantages of this method are obvious: high TTNs and high selectivity can be 
achieved; reaction for desired product can be easily coupled with cofactor 
recycling process.  
As early as 1980s, Wong et al. demonstrated an efficient NADH recycling 
method with the use of glucose and glucose dehydrogenase (GDH) from 
Bacillus cereus (Scheme 2.14).127,128 In a synthesis of D-lactate, NADH was 
cycled 36,000 times with no loss in GDH activity. The GDH from B. cereus is 
extremely stable and accepts both NAD+ and NADP+ with high specific 
activity. Glucose as a strong reducing agent is easily available and innocuous 
to enzymes. 
 






























2.4.3.2 Electrochemical method 
 
Electrochemical methods are attractive since cofactors only switch between 
the oxidized and reduced forms. Direct cathodic reductions129 without any 
auxiliary devices in recycling were widely studied in 1980s. However, this 
kind of approaches suffer from low regioselectivity and side reactions because 
of the high over-potentials, electrode fouling and dimerization of the cofactor, 
the correct regioisomer can be regenerated only in 0 to 75% yield. Therefore, 
indirect electrochemical reduction of NAD(P)+, using electron transport agents 
as mediators which is an attractive alternative to direct reduction methods was 
developed (Scheme 2.15).130-132 A large number of mediators have been 
examined with viologens, anthraquinones and [Cp*Rh(bpy)Cl]Cl receiving 
much attention. For example, Hollmann et al. reported the first 
electrochemical NADH recycling coupled to a monooxygenase reaction using 










Regeneration Synthesis  
Scheme 2.15 Electrochemical reduction for NAD(P)+ recycling. 
 
Challenge in this approach is to create efficient electrochemical chain to 
transfer electrons. When designing reactors, stability of enzyme is an 
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important factor as well. Though this problem can be addressed by 
immobilization on electrode’s surface, only a few relatively stable 
oxidoreductases can be immobilized. Fragile enzymes can be hardly 
immobilized due to great loss of activity.  
 
2.4.3.3 Chemical method 
 
Very few examples of chemical methods of cofactor recycling have been 
found in the literature. At present, chemical methods still suffer from 
cumbersome reaction conditions, expensive and toxic reagents, side reactions, 
and low TTN. The highest TTN reached with this method was just 300 so 
far.133 Therefore, chemical approach for cofactor recycling has been not 














Scheme 2.16 Chemical method for NAD+ recycling. 
 
Bhaduri et al. reported the use of a platinum carbonyl cluster for reductive 
recycling of NAD+ to NADH by dihydrogen (Scheme 2.16).134 Since both 
NAD+ and L-LDH are only soluble in water, while the platinum carbonyl 
cluster is only soluble in organic solvents, so a biphasic system consisting of 




2.4.3.4 Photochemical method 
 
The irradiation of photo-sensitizer dyes with visible light can lead to the 
oxidation of reduced form cofactor NAD(P)H. Recently, photochemical 
methods attract more attention due to the efficient use of clean and cheap solar 
energy. Homogenous photo-sensitizers such as ruthenium or zinc complexes, 
dyes like methylene blue, and heterogeneous semiconductor powders and 
colloids like cadmium sulfide or titanium dioxide (TiO2) are generally used. 
Julliard et al.135 studied this photochemical cofactor recycling method in 
ethanol oxidation process (Scheme 2.17). In this case, a TTN of 1,125 for the 
recycling of NAD+ from NADH was achieved by using a methylene blue (MB) 
as the electron acceptor, which is able to emit energy and oxidize NADH in its 
excited state.  
 
NADH + MB+ + H+ 2e
-
NAD+ + MBH + H+  
 
Scheme 2.17 Photochemical method for NAD+ recycling. 
 
To date, enzymatic recycling methods are preferred. Because compared with 
enzymatic approaches, other strategies often lack the high selectivity required 
to achieve satisfactory high TTNs and are usually not compatible with the 






2.4.4 Approaches for enzymatic NAD(P)+ and NAD(P)H recycling 
 
For enzymatic recycling method, there are two different approaches: the 
substrate-coupled136-139 and the enzyme-coupled16-19,140 processes. Substrate-
coupled recycling uses a second substrate as driving force, while enzyme-
coupled recycling uses a second enzyme. As shown in Figure 1.2, substrate-
coupled recycling of NAD(P)H uses the same enzyme to convert substrates in 
two pathways. By contrast, there are two different enzymes using as catalysts 
in enzyme-coupled recycling.  
 
2.4.4.1 Substrate-coupled approach 
 
Some enzymes are capable of catalyzing the oxidation and reduction of 
several substrates in reversible reactions. By adding two substrates, one in the 
reduced form and the other in the oxidized form, a cofactor recycling system 
can be created. 
In substrate-coupled approach, only one enzyme is involved, which simplifies 
purification process comparing with complicated isolation process in enzyme-
coupled approach. However, it is not easy to find a suitable second substrate 
for the recycling of the cofactor. Moreover, in substrate-coupled reaction 
system, there is a competition between substrate, product, cosubstrate and 
coproduct. In order to achieve high yield, a large excess of alcohol or in situ 
product removal (ISPR) processes should be used to drive equilibrium towards 




2.4.4.2 Enzyme-coupled approach 
 
In enzyme-coupled approach, a second enzyme and its substrate are added. 
The utilization of the auxiliary enzyme facilitates to create a cycle for cofactor 
recycling.  
Of course it adds to the cost and complexity of the system with adding an 
extra enzyme, however, this method is superior to substrate-coupled one in 
terms of product isolation. In this case, the second enzyme and its substrate 
can be chosen to achieve a favorable equilibrium position in the primary 
reaction. For instance, formate dehydrogenase (FDH) is favorable due to its 
product carbon dioxide, which can be easily removed from solid or liquid 
system. Many methods using a second enzyme have been developed and 
widely used for the recycling of nicotinamide cofactors in both aqueous media 
and organic media.  
Both whole cell containing necessary enzymes and isolated enzymes are 
capable in NAD(P)+ and NAD(P)H recycling. While approaches based on 
isolated enzymes are expensive and less stable, approaches based on whole 
cells containing necessary enzymes depend on the amount of intracellular 




2.5 Cell Permeabilization 
 
The cell wall and the cellular membrane of microbial cells provide semi-




                             
 
                                      
 
Figure 2.10. Structures of (a) Gram-negative and (b) Gram-positive outer cell layers. 
 
negative and Gram-positive (Fig.2.10) strains have different membrane 
structures. The outmost cell layer of Gram-negative bacteria is an outer 
membrane called envelops, which is a bilayer structure composed of 
lipopolysaccharide (LPS) and phospholipids, and it is a good barrier for both 
hydrophobic and hydrophilic molecules. There is also a thin layer of 
peptidoglycan and a periplasmic space situated between the outer membrane 
and the peptidoglycan in Gram-negative strain cells. Different from Gram-
negative bacteria, most Gram-positive bacteria are surrounded by a thick 
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too coarse and poses little resistance to the diffusion of small molecules, the 
cell wall is mechanically very strong and completely impermeable to big 
molecules including nicotinamide cofactors.141 
 
 
2.5.1 Reasons for cell permeabilization 
 
Whole cells can be made permeable by chemical or physical treatment to 
allow or improve the conversion of substrates to useful products. Cell 
permeabilization has been widely applied to increase productivity since the 
permeabilized cells have better access to substrate and better release of 
product.  
It is also possible of utilizing permeabilized cells for cofactor recycling, since 
both Gram-negative and Gram-positive whole cells can be made permeable to 
nicotinamide cofactor by chemical or physical treatment. 
 
2.5.2 Methods for cell permeabilization 
 
To date, solvent treatment, detergent treatment, salt stress, freeze and thaw, 
electropermeabilization, organic reagents such as EDTA as permeabilizer, 








2.5.2.1 Solvent treatment & detergent treatment 
 
M. Canovas et al.142,143 showed in a permeabilization study with Escherichia 
coli strains that permeabilization of cells improved the yield of L-carnitine 
obtained and cell activity when crotonobetaine was used as substrate. A higher 
cell activity was observed with organic solvents such as acetone, ethanol, iso-
propanol and toluene (65-70% yield), detergents such as Triton X-100 and 
Tween 20 (70-75% yield) and polyethylenimine (80-89% yield).   
 
2.5.2.2 Salt stress 
 
M. Canovas et al. also studied the salt stress effect to the production of L-
carnitine of E. coli cells. The whole-cell catalyzed reaction was carried out in 
the presence of NaCl. Product yield was increased with the increase of the 
NaCl concentration in the reaction medium. When NaCl concentration reached 
0.5 M, the product yield was doubled (from 40% to 80%) compared with that 
of the control reaction without the salt.144 
 
2.5.2.3 Freeze and thaw 
 
M. W. Breedveld et al. investigated the synthesis of cyclic "-(1,2)-glucans 
from UDP-[14C]glucose by whole cells of Rhizobium leguminosarum bv. 
trifolii TA-1.  With resting cells of TA-1, no excretion of glucan was observed; 
however, after these cells were alternately frozen and thawed eight times, they 





R. Y. K. Yang et al. investigated the use of low-level electric currents and 
voltages to release and collect intracellular secondary metabolites from living 
plant cells. Indole alkaloids, ajamlicine, and yohimbine were extracted from 
Catharanthus roseus cells by applying 1-5 mA electric current in the 
membrane reactors, and they were also simultaneously collected by 
electrophoresis.146 
 
2.5.2.5 Genetic method 
 
The development of chemical or physical treatment permeabilization is mainly 
replied on trial-and-error manner. However, with the development of 
recombinant DNA technology, permeability issues can be addressed in a more 
predictable manner. Cell surface display, modification of outer membrane 
structures, expressing membrane-active peptides, etc., have been exploited 
fruitfully to improve cell permeability. 
Ni and Chen reported that they successfully altered E. coli outer membrane 
structures by genetic method. Typically, a LPS mutant SM101 and a Braun’s 
lipoprotein mutant E609L were used along with two model substrates 
nitrocefin and a tetrapeptide N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide. The 
reduction of the outer membrane permeability by genetic methods led to 





2.5.3 Applications of permeabilized cells for cofactor recycling 
 
Cell permeabilization is widely applied to increase productivity since the 
permeabilized cells have better access to substrate and better release of 
product. It is also possible of utilizing permeabilized cells for cofactor 
recycling. In fact, both Gram-negative and Gram-positive whole cells can be 
made permeable to nicotinamide cofactor by chemical or physical treatment. 
However, only few examples of using permeabilized cells for cofactor 

















Scheme 2.18 Single permeabilized microorganism for efficient enantioselective reduction of 
ketone with cofactor recycling. 
 
Zhang et al. used the single permeabilized microorganism for bioreduction 
and simultaneous cofactor recycling. B. pumilus Phe-C3 which could catalyze 
the bioreduction of 3-ketoester was found containing an NADP+-dependent 
glucose-6-phosphate. The cells B. pumilus Phe-C3 was treated with 
EDTA/toluene to active permeabilized cells. Under optimized conditions, the 
use of permeabilized cells of B. pumilus Phe-C3 with the initial supply of 
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glucose-6-phosphate and 0.005 mM NADP+ resulted in bioreduction of 3-
ketoester with recycling of NADPH 4,220 times (Scheme 2.18).148 The high 
total turnover number (TTN) for cofactor recycling significantly reduced the 
cofactor cost for the bioreduction. However, the requirement for two enzymes 
in one microorganism and using relatively expensive glucose-6-phosphate 
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Scheme 2.19 Coupling of permeabilized microorganisms for efficient enantioselective 
reduction of ketone with cofactor recycling. 
 
Later, Zhang, et al. developed a novel coupled permeabilized microorganisms 
system for bioreduction with efficient recycling of NADPH. Permeabilized 
cells of B. pumilus Phe-C3 containing a ketoreductase were coupled with 
permeabilized cells of Bacillus subtilis BGSC 1A1 containing a GDH for 
bioreduction of 3-ketoester to produce (R)-3-hydroxyester, which resulted in a 
TTN for NADPH recycling of 1,600 with initial addition of glucose and 0.01 
mM NADP+ (Scheme 2.19).63 Though this novel system was rather promising, 
the TTN for cofactor recycling and final product concentration need to be 
further improved in order to make this system more economically practical.  
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Compared with isolated enzymes, permeabilized cells are much cheaper and 
more stable; compared with whole cells, permeabilized cells allow the use of 
extracellular cofactor and increase the substrate and product permeability. 
Thus, the use of easily available permeabilized cells for oxidoreductions with 
cofactor recycling might be of advantage over the isolated enzymes or whole 
cells approaches.   
 
2.6 Tandem Biocatalyses 
 
Tandem catalyses are processes in which multiple catalysts operate 
concurrently in one pot to enable cascade reactions, circumventing the often 
time-consuming and yield-reducing isolation and purification of intermediates 
in multistep synthesis.149 
 
2.6.1 Advantages and applications of tandem catalyses 
 
The advantages of tandem catalyses over conventional chemistry are clearly 
illustrated in Figure 1.4.150 In traditional catalysis, starting material A is 
converted step-by-step to final product D, and intermediates B and C are 
isolated and purified in each conversion step (Figure 1.4.a). In tandem 
catalysis, final product D is directly produced from starting material A through 
multistep reactions in one pot, without separation of intermediates B and C 
(Figure 1.4.b). This one-pot approach can increase product yield, use less 




A variety of promising tandem catalyses have been described in the literature, 
involving different combinations of enzymes, homogeneous and 
heterogeneous catalysts. According to the catalytic types of involved in the 
system, tandem catalyses can be categorized into chemo-chemo tandem 
catalysis, chemo-bio tandem catalysis and bio-bio tandem catalysis. 
 
2.6.1.1 Chemo-chemo tandem catalysis 
 
Chemo-chemo tandem catalysis has been applied in the fields of carbonylation, 






























Scheme 2.20 Diastereoselective tandem hydroformylation olefination, hydrogenation 




Breit et al. functionalized alkenes by hydroformylation, olefination, and then 
hydrogenation (Scheme 2.20). They carried out a diastereoselective 
transformation of a substituted allylic alcohol using the chiral directing group 
ortho-diphenylphosphanyl benzoate. It was found that under hydroformylation 
conditions, mono-substituted ylides could be used to generate the 
corresponding $, "- unsaturated ketone or ester. Then the newly produced 
olefin underwent metal catalyzed hydrogenation to form ester.107 Another very 
illustrative example showing the chemo-chemo tandem catalysis was the 
combination of proline-catalyzed cross-aldol reaction with Barbier-type 




















Scheme 2.21 Combined one-pot proline-catalyzed aldol reaction/indium-mediated allylation. 
 
2.6.1.2 Chemo-bio tandem catalysis 
 
There is an increase in the number of papers published about chemo-bio 
tandem catalysis as one-pot operation for the production of fine chemicals, 









chemo racemisation + bio enantioselectivity  
Scheme 2.22 Dynamic kinetic resolution by chemo-bio tandem catalysis. 
 
One distinctive example is the dynamic kinetic resolution (DKR) by the use of 
a chemocatalyst and a biocatalyst in one pot (Scheme 2.22). Through such a 
combination, so called 100% ee and 100% yield synthesis of enantiopure 
compounds is possibly to be achieved from racemic starting materials. 
Otherwise, the maximum yield can be obtained is only 50%. A number of 
examples of such DKR have been reported. For instance, Jung et al. reported 
the combination of ruthenium catalyzing ketone and imine hydrogenation with 












Scheme 2.23 Hydrogenation of ketone combined with dynamic kinetic resolution. 
 
Although many chemo-chemo or chemo-bio tandem catalyses have been 
demonstrated, most of them are two-step reactions. Three- or more steps 
chemo-chemo or chemo-bio tandem catalyses are still rare, mainly due to the 
incompatibility of many chemo-catalytic reactions or chemo-catalytic with 
54 
 
enzymatic conversions in terms of reagents, solvent, pH and temperature. 
 
2.6.2 Advantages and applications of tandem biocatalyses 
 
Tandem biocatalysis is a process in which multiple biocatalysts catalyze 
multiple-step enzymatic reactions in one pot without intermediates recovery. 
Except the general advantages of tandem catalysis, such as avoiding the time-
consuming, yield-decreasing and waste-producing intermediates, tandem 
biocatalysis also has all the advantages of biocatalysis, including high 
selectivity and mild reaction conditions. Recently, tandem biocatalysis has 
drawn significant attention in chemical and pharmaceutical synthesis, and 
development of tandem biocatalysis is regarded as one of the most important 





Tetralin (R)-1-tetralol 1-tetralone  
 
Scheme 2.24 Sequential oxidations of tetralin into 1-tetralone with single microorganism. 
 
Some single microorganism demonstrated the ability to catalyze tandem 
bioconversions, but their efficiencies were low, especially when using non-
natural compounds as substrate. For instance, M. isabellina was reported to be 
able to sequentially oxidize tetralin into 1-tetralone. However, only 2.72 mM 




Alternatively, developing tandem biocatalysts systems for tandem 



























Scheme 2.25 Tandem biocatalysts system with immobilized chloroperoxidase and glucose 
oxidase. 
 
Many tandem biocatalysts systems including one biocatalyst for in situ 
cofactor recycling or in situ oxidant generation have been reported. For 
example, indole was oxidized into 2-indolinone using chloroperoxidase and 
glucose oxidase immobilized on SBA-15 as tandem biocatalysts (Scheme 
2.25). Chloroperoxidase (CPO) from Caldariomyces fumago was immobilized 
on molecular sieve SBA-15 and applied to the oxidation of indole with 
hydrogen peroxide as oxidant. Through such in situ hydrogen peroxide 
generation by glucose oxidation with glucose oxidase (GOx) immobilized on 
SBA-15, the deactivation of peroxidase by addition of hydrogen peroxide was 
prevented.156 In another tandem biocatalysts system, LeuDH was used to 
catalyze the reductive amination of trimethylpyruvate to L-tert-leucine, while 
















Scheme 2.26 Tandem biocatalysts system for L-tert-leucine synthesis with cofactor recycling. 
 
In terms of tandem biocatalysts systems for sequential biotransformations, 
only limited examples have been reported. For example, Xu et al. 
demonstrated asymmetric dihydroxylation of aryl olefins with tandem 
biocatalysis in two-biocatalyst system: one containing an enantioselective 
styrene monooxygenase, and the other containing a regioselective epoxide 
hydrolase (Scheme 2.27). By this method, chiral aryl vicinal diols were 












R=H, 4-Cl, 3-Cl, or 2-Cl Up to > 99% ee
Up to 95% yield  
 
Scheme 2.27 Tandem biocatalysts systems for asymmetric dihydroxylation of aryl. 
 
2.6.3 Tandem biocatalysts systems for sequential oxidoreductions  
 
Although in nature, it is quite common that a single microorganism containing 
multiple enzymes can uptake and metabolize nature compound such as 
glucose, it is not easy to find and array appropriate multiple biocatalysts to 
carry out sequential bioconversions, especially for efficient oxidoreductions. 
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Firstly, it is difficult to develop a tandem biocatalysts system, especially for 
the conversion of non-natural compound. For the development of a tandem 
biocatalysts system, one of the most important considerations is biocatalysts 
compatibility, since there always are diverging reaction conditions required for 
single-step bioconversion. The two or more biocatalysts should not only be 
able to function well in the presence of others, they also should be compatible 
with any solvents, reagents, temperatures, pH that they might come across 
throughout the course of the whole reaction. The steps must be balanced 
carefully to ensure that the catalytic processes run at comparable rates, and the 
different catalytic reactions do not interfere with others. These issues are more 
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Scheme 2.28 Tandem biocatalysts system for the deracemization of racemic secondary 
alcohols through an oxidation-reduction sequence. 
 
Moreover, most enzymatic oxidoreductions require stoichiometric amount 
expensive cofactors, which are usually quite expensive. These cofactors act as 
transport metabolites, transporting hydrogen, oxygen or electrons on the one 
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hand, or other atoms or molecules on the other, between different parallel 
reactions. For example, P450 hydroxylation system needs NADPH for 
electron transfer. For practical application of oxidoreductions, expensive 
cofactor needs to be efficiently recycled.  
To date, in terms of sequential transformations with tandem biocatalysts 
systems in organic synthesis, only two deracemization examples have been 
reported. One example is the sequential oxidation-reduction for 
deracemization of secondary alcohol (Scheme 2.28),60,61 the other is the 
sequential oxidation-reduction for deracemization of hydroxy acid.62 When it 
comes to enzymatic sequential oxidations with tandem biocatalysts systems, 
due to the complicacy of its electron transfer system and the variety of its 
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Biocatalytic oxidoreductions are important reactions in asymmetric synthesis, 
with great potential in industrial production of enantiopure chemicals and 
pharmaceuticals.2-6 These reactions often need stoichiometric amount of the 
expensive cofactor NAD(P)H or NAD(P)+, thus their practical application 
requires the efficient recycling of the necessary cofactor.7-14 In general, 
cofactor recycling can be achieved by the coupling of a desired enzymatic 
reaction with an additional chemical, electrochemical, photocatalytic or 
enzymatic reaction, among which the enzymatic method is favored.7-14,162 
Enzymatic cofactor recycling can be realized by “coupled substrates”138,163-165 
and “coupled enzymes” 15-23 approaches. The latter is more general and utilizes 
the first enzyme for the desired biotransformation and the second one for 
cofactor recycling. Formate dehydrogenase (FDH)17,18 and glucose 
dehydrogenase (GDH)16,23 are well-known enzymes for the recycling of 
NADH and NADPH, respectively. The “coupled enzymes” approach has been 
successfully applied via two isolated enzymes16-19,23 or whole cells20-22 of a 
microorganism co-expressing the two necessary enzymes. While the use of 
isolated enzymes is still costly, the use of whole cells depends on the 
availability of intracellular cofactor, which may be limiting and cannot be 
altered by the addition of extracellular co-factor. On the other hand, whole 
cells can be made permeable to NAD(P)H and NAD(P)+ by the treatment with 
organic solvent/detergent while keeping high enzymatic activity. 22,142,147,166 
Thus, the use of easily available permeabilized cells for oxidoreductions with 
cofactor recycling might be of advantage over the isolated enzymes or whole 
cells approaches.   
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We recently discovered that Bacillus pumilus Phe-C3 containing a NADPH-
dependent ketoreductase catalyzed the enantioselective reduction of ethyl 3-
keto-4-triflurobutyrate 1 giving the corresponding product 3-hydroxyester (R)-
2 in 95% ee,167 a useful intermediate for the preparation of the antidepressant 
Befloxatone.168 This strain was also found to contain a NADP+-dependent 
glucose-6-phosphate dehydrogenase.148 Treatment of the cells of B. pumilus 
Phe-C3 with EDTA/toluene gave active permeabilized cells that catalyzed the 
bioreduction of 3-ketoester 1 and the recycling of NADPH.148 Under 
optimized conditions, the use of permeabilized cells of B. pumilus  Phe-C3 
with the initial supplying of glucose-6-phosphate and 0.005 mM NADP+ 
afforded the bioreduction of 3-ketoester 1 with the recycling of NADPH for 
4220 times (Figure 3.1).148 The high TTN of the cofactor recycling 
significantly reduced the cofactor cost in the bioreduction. However, the 
requirement of having two necessary enzymes in one microorganism and the 
using of relatively expensive glucose-6-phosphate may limit the application 
scope of the single permeabilized microorganism approach. To solve these 
problems, we recently developed a novel and general approach of using two 
permeabilized microorganisms for bioreduction with cofactor recycling:63 
permeabilized cells of B. pumilus Phe-C3 containing a ketoreductase were 
coupled with permeabilized cells of Bacillus subtilis BGSC 1A1 containing a 
GDH169 for the bioreduction of 3-ketoester 1 to produce 3-hydroxyester (R)-2, 
giving a total turnover number (TTN) for NADPH recycling of 1600 with the 
initial addition of glucose and 0.01 mM NADP+. Several advantages were 
demonstrated: compared with whole cells, this approach enables the use of the 



















a) Via a single permeabilized microorganism containing ketoreductase and glucose 6-phosphate dehydrogenase




Permeabilized B. subtilis BGSC 1A1 
Permeabilized E. coli XL-1 Blue (pGDH1)











b) Via coupled permeabilized microorganisms containing ketoreductase and glucose dehydrogenase, respectively
TTN = 1620 
TTN = 3100 (this study)
TTN = 4200 (this study)
 
 
Figure 3.1. Bioreduction with NADPH recycling by using permeabilized microorganisms. 
OEt, OC2H5; G-6-PDH, glucose-6-phosphate dehydrogenase; 1, ethyl 3-keto-4,4,4-
trifluorobutyrate; (R)-2, (R)-ethyl 3-hydroxy-4,4,4-trifluorobutyrate. 
 
allows for easy substrate access and easy product release; compared with the 
isolated enzyme, permeabilized cells are cheap, easily available in large 
amount, active for a longer period, stable, and reusable. The coupled 
permeabilized cells approachis of great application potential also due to the 
general applicability, in addition to the above demonstrated advantages. 
However, the highest total turnover number (TTN) for NADPH recycling 
from this approach has been so far only 1620. The main reason is the relative 
low activity of the whole cell biocatalyst for cofactor recycling. To make this 
method suitable for practical syntheses of fine chemicals, the TTN of the 
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expensive cofactor has to be significantly increased. To achieve this goal, we 
aim to develop better cofactor-regenerating systems, better permeabilized cells 
couple, and efficient synthesis of 3-hydroxyester (R)-2 by the use of the new 
biocatalyst system.  
 




Nicotinamide adenine dinucleotide phosphate (NADP+, > 99%), nicotinamide 
adenine dinucleotide (NAD+, > 99%), ampicillin (> 99%), and ethyl 3-keto-4, 
4, 4-triflurobutyrate 1 (> 98%) were purchased from Sigma-Aldrich. Isopropyl 
!-D-thiogalactopyranoside (ITPG, > 99%) was bought from 1st BASE. 
Medium components tryptone and yeast extract were purchased from Biomed 
Diagnostics. Ethyl 3-hydroxyl-4, 4, 4-trifluorobutanoate 2 was prepared 
according to the published procedures.159 
 
3.2.2 Analytical methods 
 
The assays of GDH activity and NADPH or NADH oxidase activity were 
carried out on Shimadzu UV-Vis 1700 spectrophotometer with Time-scan 
function. The concentrations of ethyl 3-keto-4, 4, 4-triflurobutyrate 1 and 
ethyl-3- hydroxyl-4, 4, 4-trifluoro-butanoate 2 were analyzed by Agilent GC 
6890 on an Agilent HP-5 column (25 m x 0.32 mm) with inlet temperature of 
290 ºC and detector temperature of 310 ºC. Temperature program: 50 ºC for 8 
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min, increase to 300 ºC at a rate of 50 ºC/min, keep at 300 ºC for 2 min. 
Retention time: 2.8 min and 9.3 min for 3-ketoester 1; 6.2 min for 3-
hydroxyester 2; 12.5 min for n-hexadecane. The ee of (R)-ethyl-3-hydroxyl-4, 
4, 4-trifluoro-butanoate 2 was analyzed by Agilent GC 6890 with a chiral 
column: Lipodex-A (25 m x 0.25 mm); temperature program: 40 ºC to 120 ºC 
at a rate of 5 ºC/min, increase to 170 ºC at a rate of 45 ºC/min; retention time: 
11.9 min for 3-hydroxyester (S)-2 and 12.2 min for 3-hydroxyester (R)-2. 
 
3.2.3 Strains and cultivation media 
 
Bacillus subtilis BGSC 1A1 was obtained from the Bacillus Genetic Stock 
Centre at the Ohio State University; Escherichia coli XL-1 Blue, Escherichia 
coli BL21, and Bacillus pumilus Phe-C322 were from the collection of our 
laboratories. The cells of B. pumilus Phe-C3 were grown in E2 medium on 
glucose (1% w/v) at 25 ºC in 2 L fermenter, and the cells were harvested and 
permeabilized according to the previously reported procedure.145 E. coli XL-1 
Blue (pGDH1) and E. coli BL21 (pGDH1) were grown in LB medium 
containing ampicillin (100 g/mL).  
 
3.2.4 Genetic engineering of E. coli XL-1 Blue (pGDH1) and E. coli BL21 
(pGDH1) 
 
Genomic DNA of B. subtilis BGSC 1A1 was obtained using Trizol Reagent 
(sigma), according to manufacture instructions. The full length GDH was 
amplified by high fidelity polymerase chain reaction with GDH primers. The 
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genomic DNA was used as the template. The primer 1 (BSG-TAA1) 
(5’GGTAAGCTTCTCGAGTTAACCGCGG CCTGCCTG3’) and primer 2 
(BSG-ATG1) (5’CAGGAATTCATACATGTATCCAGATTTAAAAGGAA 
3’) were designed according to the nucleotide sequence of GDH of Bacillus 
subtilis BGSC 1A1. The primers contained the restriction sites for Hind III in 
the primer 1 and EcoRI in the primer 2, respectively. The amplification 
condition for 817 bps PCR product was: 95 ºC for 5 min (hot start), followed 
by 30 cycles of 95 ºC for 45 s, 55 ºC for 45 s, 72 ºC for 45 s, and finally 72 ºC 
for 7 min. The GDH fragment was digested with EcoR I (Roche) and Hind III 
(Roche) for 90 min at 37 ºC, and was inserted into the lacZ expression vector 
pUC18 through these restriction enzyme sites to form pGDH1.  
E. coli XL-1 Blue cells were made chemically competent and were then 
transformed with pGDH1. The insertion was confirmed by plasmid prep 
(QIAGEN) from cell culture and restriction digest analysis using EcoR I and 
Hind III. The GDH protein was expressed in recombinant E. coli XL-1 Blue 
by using the inducible lac promoter under control of the presence of isopropyl-
!-D-thiogalactopyranoside (IPTG). Similarly, plasmid pGDH1 was transferred 
into E. coli BL21 by electroporation method.  
 
3.2.5 Growth and GDH activity of E. coli BL21 (pGDH1) and E. coli XL-1 
Blue (pGDH1) 
 
Both strains were inoculated on LB agar plate (10 g Tryptone, 5 g yeast 
extract and 5 g NaCl in 1 L deionized water with 1.5% agar) containing 
ampicillin (100 "g/mL) and grown overnight at 37 ºC, respectively. A single 
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colony from the LB agar plate of each strain was inoculated into 100 mL of 
LB medium with ampicillin (100 "g/mL) and grown at 250 rpm and 37 ºC for 
12 h, giving an OD450 of 8.0 (cell density of 2.2 g cdw/L) for E. coli BL21 
(pGDH1) and an OD450 of 6.0 (cell density of 1.7 g cdw/L) for E. coli XL-1 
Blue (pGDH1), respectively. 
To obtain high hydroxylase activity of this recombinant strain, culture 
condition was optimized, including inducing time (1.5 to 2.5 h after 
inoculation), inducing duration (2 to 6 h), inducing amount (0.3 to 1.0 mM 
IPTG) and inducing temperature (25 to 37ºC). The optimal culture procedure 
is: 12 mL of the above preculture of E. coli BL21 (pGDH1) were added in LB 
(800 mL) medium containing ampicillin (100 "g/mL) and the mixture was 
shaken at 250 rpm and 37 ºC. Samples (1 mL) were taken at different time 
points for OD measurement and activity test. IPTG (1 mM) was added when 
OD450 reached 1.8 (cell density of 0.5 g cdw/L) at 2.5 h. The cells were 
harvested at the late exponential phase with an OD450 of 5.8 (cell density of 
1.6 g cdw/L) at 6 h, washed with KP buffer (5 mM, pH = 7.5), and then stored 
in -80 ºC freezer. 
12 mL of above prepared preculture of E. coli XL-1 Blue (pGDH1) were 
added in LB (600 mL) medium containing ampicillin (100 "g/mL) and the 
mixture was shaken at 250 rpm and 37 ºC. Samples (1 mL) were taken at 
different time points for OD measurement and activity test. IPTG (1 mM) was 
added when OD450 reached 1.2 (cell density of 0.3 g cdw/L) at 3 h. The cells 
were harvested at the late exponential phase with an OD450 of 7.2 (cell density 
of 2.0 g cdw/L) at 10 h, washed with KP buffer (5 mM, pH = 7.5), and then 
stored in -80 ºC.  
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To test the GDH activity, 7 mL cell suspensions (10 g cdw/L) of  each 
recombinant E. coli in KP buffer (50 mM, pH = 7.5) were passed through a 
homogenizer (Constant Cell Disruption System™) twice at 20 kpsi. The cell 
debris was removed by centrifugation at 13,000 g at 4 ºC for 30 min. The 
supernatant was diluted 10 times with KP buffer (50 mM, pH = 7.5), and the 
protein concentration was determined as 0.4 g protein/L by Bradford protein 
content assay170 with bovine serum albumin (BSA) as standard. To 940 "L of 
the prepared CFE was added 50 "L glucose stock solution (2.0 M), 10 "L 
NADP+ solution (0.2 M). The formation of NADPH was followed by UV 
absorption at 340 nm at 25 ºC, and the concentration was calculated by using 
#340 of 6.22 L*mmol-1. The specific GDH activity was given as U (the 
formation of 1 "mol NADPH per minute)/g protein.  
SDS-PAGE was performed by loading 15 "L CFE (0.21 g protein/L) on a gel 
containing 0.1% sodium dodecyl sulfate and 10% acrylamide, staining with a 
0.1% solution of Commassie brilliant blue R-250 in methanol/acetic 
acid/water (4:1:5; v/v/v), and destaining by soaking in deionized water 
overnight.  
 
3.2.6 Preparation and GDH Activity of permeabilized cells of E. coli BL21 
(pGDH1) and E. coli XL-1 Blue (pGDH1) 
 
The frozen cells of E. coli BL21 (pGDH1) and E. coli XL-1 Blue (pGDH1) 
were thawed for 2 h and resuspended in Tris-HCl buffer (100 mM, pH = 8.0) 
to a density of 10 g cdw/L, respectively. For E. coli BL21 (pGDH1), EDTA 
(10 mM) and toluene (1% v/v) were added, and the mixture was shaken at 300 
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rpm and 25 °C for 10 min. For E. coli XL-1 Blue (pGDH1) EDTA (5 mM) 
was added, and the mixture was shaken at 300 rpm and 25 °C for 30 min 
followed by incubation at 4 °C for 1 h. The permeabilized cells were obtained 
by centrifugation at 4 °C and 3,320 g for 10 min, and their GDH activity assay 
was performed by the bioconversion of glucose (55 mM) with permeabilized 
cells (0.2 g cdw/L) in Tris-HCl buffer (100 mL, pH = 7.0) in the presence of 
NADP+ (2 mM) on 1 mL scale at 25 ºC and determined by following NADPH 
formation at 340 nm. 
 
3.2.7 Kinetics of GDH activity of the permeabilized cells of E. coli BL21 
(pGDH1) 
 
To 900-945 "L permeabilized cells of E. coli BL21 (pGDH1) (0.2 g cdw/L) in 
Tris-HCl buffer (100 mM, pH = 7.0) were added 50 "L glucose stock solution 
(2.0 M), 5-50 "L NADP+or NAD+ (0.02 M). The reaction was followed by the 
UV absorbance at 340 nm at 25 ºC. The initial velocities were obtained from 
the curves of NADPH or NADH concentrations vs. time, and they were used 
to plot 1/[v] vs. 1/[S].171 
 
3.2.8 NADPH and NADH oxidase activities of the permeabilized cells of E. 
coli BL21 (pGDH1) 
 
The permeabilized cells were resuspended in 990 "L Tris-HCl buffer (100 
mM, pH = 7.0) to a density of 0.2 g cdw/L. 10 "L NADPH or NADH (0.2 M) 
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were added. The concentration of NADPH or NADH was followed by UV 
absorption at 340 nm at 25 °C.  
 
3.2.9 General procedure for bioreduction of ethyl 3-keto-4, 4, 4-
triflurobutyrate 1 with NADPH recycling with coupled permeabilized 
microorganisms 
 
To a suspension of permeabilized cells of B. pumilus Phe-C3 (20-40 g/cdw) 
and E. coli XL-1 Blue (pGDH1) or E. coli BL21 (pGDH1) (20-40 g/cdw) in 
10 mL Tris-HCl buffer (100 mM, pH = 7.0) was added 3-ketoester 1 (110 mg, 
60 mM), NADP+ (0.04 mg, 0.005 mM), and glucose (0.8 g, 440 mM). The 
mixture was shaken at 25 ºC and 300 rpm and aliquots (300 "L) were taken at 
different time points for GC analysis. Additional 3-ketoester 1 (97 mg, 60 mM) 
was added at 5 h. More glucose (1.5-2.0 M) was added at several time points. 
Analytic samples were prepared by centrifugation, dilution to 4 times volume, 
extraction with same volume chloroform containing 2 mM hexadecane as the 
internal standard, and desiccation with anhydrous Na2SO4. GC analysis gave 
the product concentration at different time points, and final TTN of NADPH 







3.2.10 Bioreduction of ethyl 3-keto-4, 4, 4-triflurobutyrate 1 with NADPH 
recycling for 4200 times with coupled permeabilized cells of B. pumilus 
Phe-C3 and E. coli BL21 (pGDH1) 
 
To a suspension of permeabilized cells of B. pumilus Phe-C3 (40 g cdw/L) 
with E. coli BL21 (pGDH1) (20 g cdw/L) in 10 mL Tris-HCl buffer (100 mM, 
pH = 7.0) was added 3-ketoester 1 (110 mg, 60 mM), NADP+ (0.04 mg, 0.005 
mM), and glucose (0.8 g, 440 mM). The mixture was shaken at 25 ºC, 300 
rpm.  Additional 3-ketoester 1 (97 mg, 60 mM) was added at 5 h. More 
glucose was added at 5 h (0.70 g, 440 mM), 10 h (0.67 g, 440 mM), 19 h (0.65 
g, 440 mM), 24 h (0.16 g, 110 mM), 29 h (0.15 g, 110 mM). At different time 
points, analytic samples were taken, prepared using the same method 
described above, and analyzed by GC.  
 
3.2.11 Bioreduction of ethyl 3-keto-4, 4, 4-triflurobutyrate 1 with NADPH 
recycling for 96 h by using coupled permeabilized cells of B. pumilus Phe-
C3 and E. coli BL21 (pGDH1) with four-times addition of 0.005 mM 
NADP+ 
 
The above reaction procedure was repeated till 24 h. Additional NADP+ (0.005 
mM) was added at 24, 48, and 72 h. More glucose was added at 24 h (0.16 g, 
110 mM), 29 h (0.15 g, 110 mM), 34 h (0.57 g, 440 mM), 44 h (0.55 g, 440 
mM), 48 h (0.13 g, 110 mM), 53 h (0.12 g, 110 mM), 58 h (0.48 g, 440 mM), 
68 h (0.47 g, 440 mM), 72 h (0.11 g, 110 mM), 77 h (0.10 g, 110 mM), 82 h 
(0.38 g, 440 mM) and 92 h (0.36 g, 440 mM). At different time points, 
71 
 
samples were taken, prepared using the same method described above, and 
analyzed by GC. The reaction was stopped at 96 h. 
 
3.3 Results and Discussion  
 
3.3.1 Genetic engineering, cell growth, and GDH activity of recombinant 
E. coli expressing GDH  
 
Previously, permeabilized cells of B. subtilis BGSC 1A1 containing GDH 
were used for the recycling of NADPH in the coupled permeabilized cells 
approach.63 The GDH activity was, however, only about 5.0 U/g cdw,63 which 
is the limiting factor for achieving high cofactor TTN. In addition, this strain 
was found to have NADPH oxidase activity, which competed with the 
NADPH-dependent bioreduction. Thus, our first target was to engineer a 
recombinant strain expressing GDH from B. subtilis BGSC 1A1 with higher 
GDH activity and no NADPH oxidase activity.  
Two primers BSG-TAA1 and BSG-ATG1 were designed for the cloning of 
the gdh gene of B. subtilis BGSC 1A1 based on the known gene sequence.169 
The full length of gdh gene was amplified by high fidelity polymerase chain 
reaction with the primers. The gdh gene fragment was digested with EcoR I 
(Roche) and Hind III (Roche) and inserted into the lacZ expression vector 
pUC18. The formed pGDH1 was then transformed into E. coli XL-1 Blue and 
E. coli BL21, respectively. The two recombinant E. coli strains were grown in 
LB medium containing ampicillin (100"g/mL) at 37ºC, respectively, and their 
GDHs were induced by the addition of 0.5-1.0 mM isopropyl-!-D-
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thiogalactopyranoside (IPTG) after the lag phase. Typical growth curves were 
shown in Fig.3.2. E. coli BL21 (pGDH1) grew faster at the beginning and 
reached the exponential phase at 5 h with a cell density of 1.5 g cdw/L. On the 
other hand, E. coli XL-1 Blue (pGDH1) grew slower at the beginning and 
reached the stationary phase at 10 h with a cell density of 2.0 g cdw/L. 
 
              
 
Figure 3.2. Growth and GDH activities of E. coli XL-1 Blue (pGDH1) and E. coli BL21 
(pGDH1). Cell growth: E. coli XL-1 Blue (pGDH1) ($); E. coli BL21 (pGDH1). GDH 
activity of CFE (-); E. coli XL-1 Blue (pGDH1) (%); E. coli BL21 (pGDH1) (&). 
 
Conditions for cell growth and GDH expression were examined. The GDH 
activity at different time points was measured by taking samples from the E. 
coli cultivation, preparing cell-free extract (CFE), determining the protein 
concentration by bioassay,170 and examining the GDH activity by adding 1% 
glucose and 2 mM NADP+ to the CFE and following the NADPH formation 
by UV absorption at 340 nm. In fact, the temperature from 20 to 37 °C and 
IPTG concentration from 0.5 to1.0 mM did not influence the GDH activity 
and expression, and induction at early stage is necessary. For both E. coli 
strains, high activity was found in the stationary phase over a period of 4-6 h. 














































coli BL21 (pGDH1) and 70 U/g protein at 10 h for E. coli XL-1 Blue 
(pGDH1), respectively, are much higher than that of the wild-type Bacillus 
strain. 
                           
 
 
Figure 3.3. SDS-PAGE of E. coli BL21 (pGDH1) (lane 1), E. coli BL21 pUC18 (lane 2), E. 
coli XL-1 Blue (pGDH1) (lane 3), and B. subtilis BGSC 1A1 (lane 4). 
 
The cloning and expressing of GDH in the two recombinants E. coli were 
successful, demonstrated by the observed GDH activity of the two E. coli, and 
by the GDH bands in the SDS-PAGE as well. SDS-PAGE in Figure 3.3 
showed the proteins in the CFE of E. coli BL21 (pGDH1) (lane 1), E. coli 
BL21 pUC18 (lane 2), E. coli XL-1 Blue (pGDH1) (lane 3), and B. subtilis 
BGSC 1A1 (lane 4). The GDH band was clearly visible for the two pGDH1-
containing recombinant strains, and E. coli BL21 (pGDH1) showed a higher 
















3.3.2 Preparation and GDH activity of permeabilized cells of E. coli 
recombinants expressing GDH 
 
The preparation of permeabilized cells with high activity is a very important 
step towards the successful application of the whole concept. A simple 
“freeze/thaw” treatment was firstly applied to E. coli BL21 (pGDH1) 
permeabilization. 
 
Table 3.1. Preparation conditions and GDH activities of the permeabilized cells of E. coli XL-
1 Blue (pGDH1) and E. coli BL21 (pGDH1) 
 
a) Samples were shaken at 25OC and 300 rpm for 30 min and then put on ice for 1 h.  
b) Samples were shaken at 25 OC and 300 rpm for 10 min without the treatment on ice. 
 
The GDH activity of whole cells was examined by adding 1% glucose and 2 
mM NADP+ to cell suspension in KP buffer (0.2 g cdw/L) and following the 
NADPH formation by UV absorption at 340 nm. The fresh cells of E. coli 
BL21 (pGDH1) showed no activity under such assay. However, the 
frozen/thawed cells demonstrated an activity of 25 U/g cdw, indicating the 
partial permeabilization of cells. Further freeze/thaw treatments increased the 
activity of the cells after each cycle and gave an activity of 45 U/g cdw after 5 
cycles. However, the activity decreased to 39 U/g cdw after 6 times treatment. 









1 BL21 (pGDH1) 5 0 30a 23 
2 BL21 (pGDH1) 10 0 30a 24 
3 BL21 (pGDH1) 5 1 30a 24 
4 BL21 (pGDH1) 5 0 10b 26 
5 BL21 (pGDH1) 10 0 10b 38 
6 BL21 (pGDH1) 10 1 10b 61 
7 XL-1 Blue (pGDH1) 5 0 30a 14 
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Nevertheless, the CFE of the 6-times-treated cells showed the full activity of 
170 U/g protein, indicating that GDH is stable under the treatment condition 
and cells were not fully permeabilized for cofactor across. 
The activity of permeabilized E. coli BL21 (pGDH1) cells is 39-45 U/g cdw, 
which is much lower than the theoretical value: the CFE of the resulted cells 
had an activity of 170 U/g protein; based on the assumption that 50% cdw is 
the weight of the total protein, the highest possible activity of permeabilized 
cells is 85 U/g cdw.  To prepare more active permeabilized cells of E. coli 
BL21 (pGDH1), treatment with surfactant and organic solvent were examined 
and turned out to be a better method. The cells were incubated with EDTA (5-
10 mM) containing toluene (0-1%) at 25 ºC and 300 rpm for 10-30 min, and 
the permeabilized cells were harvested by centrifugation and the GDH activity 
was determined. As shown in Table 3.1, permeabilized cells prepared by 
incubation with 10 mM EDTA containing 1% toluene for 10 min showed the 
best activity of 61 U/g cdw which is higher than the activity of 45 U/g cdw 
obtained by freeze/thaw treatment for 5 times, and close to the theoretic 
maximum for the cells. Here, the amount of toluene used is very critical. The 
use of high than 1% toluene decreased the activity. In addition, the incubation 
time is important: 10 min is better than 30 min.   
Similarly, EDTA (5-10 mM) and toluene (0-1%) were used for the treatment 
of the cells of E. coli XL-1 Blue (pGDH1). Although many conditions were 
examined, the best permeabilization condition was the treatment with 5 mM 
EDTA without toluene, giving a rather low GDH activity of 14 U/g cdw. 
Nevertheless, this is more than double of the activity of the permeabilized 
cells of the wild-type Bacillus strain. 
76 
 
3.3.3 GDH kinetics and NAD(P)H oxidase activity of E. coli BL21 
(pGDH1) 
 
To investigate the cofactor dependence and the affinity of NADP+ or NAD+ to 
the GDH in permeabilized E. coli BL21 (pGDH1), a set of activity assays 
were performed with NADP+ or NAD+ at different concentrations (0.1-1.0 
mM) in the suspension of the permeabilized cells (0.2 g cdw/L) in Tris-HCl 
buffer (100 mM, pH = 7.0) containing glucose (55 mM) at 25 ºC. The reaction 
was followed by UV absorption at 340 nm. The initial velocities at different 
concentration of NADP+ or NAD+ were used for the plot of 1/[v] vs 1/[S],171 
giving Km of 0.90 mM and Vmax of 130 U/g cdw for NADP+ and Km of 1.4 mM 
and Vmax of 76 U/g cdw for NAD+ for the permeabilized cells. Such 
permeabilized cells can be used for the recycling of NADPH and NADH. The 
value of Vmax/Km, which measures enzyme efficiency, was 2.7-fold higher for 
NADPH recycling than for NADH recycling. 
To examine NADH or NADPH oxidase activity of the permeabilized cells of 
E. coli recombinants, oxidation of NADH or NADPH was performed in cells 
suspension (0.2 g cdw/L) in Tris-HCl buffer (100 mM, pH = 7.0) in the 
presence of NADPH (2 mM) or NADH (2 mM) at 25 ºC for 30 min. The 
NADPH or NADH concentration was determined by UV absorbance at 340 
nm. In both case, no NADPH or NADH was consumed, suggesting these 




3.3.4 Coupling of permeabilized cells of B. pumilus Phe-C3 and 
recombinant E. coli expressing GDH for bioreduction of 3-ketoester 1 
with NADPH Recycling 
 
The potential of using permeabilized cells of E. coli BL21 (pGDH1) or E. coli 
XL-1 Blue (pGDH1) for cofactor recycling was examined in the 
enantioselective reduction of ethyl 3-keto-4-triflurobutyrate 1 to the 
corresponding 3-hydroxyester (R)-2. Previously, the best TTN for NADPH 
recycling in the reduction was obtained as 1600 when permeabilized cells of B. 
pumilus Phe-C3 and B. subtilis BGSC 1A1 were used in 20 g cdw/L and 40 g 
cdw/L, respectively, with initial addition of 0.01 mM NADP+.99 For 
comparison, 0.005 mM NADP+ was used for the same biotransformation, 
giving exactly the same TTN. Coupling of permeabilized cells of E. coli XL-1 
Blue (pGDH1) with an activity of 14 U/g cdw (40 g cdw/L) with 
permeabilized cells of B. pumilus Phe-C3 (20 g cdw/L) for bioreduction of 3-
ketoester 1 with initial supply of 0.005 mM NADP+ at 25 ºC and 300 rpm for 
30 h gave a TTN of 3100. 
Permeabilized cells of E. coli BL21 (pGDH1) with an activity of 24 U/g cdw, 
prepared by the treatment with EDTA (10 mM), were then examined for the 
cofactor recycling. Coupling of B. pumilus Phe-C3 (20g cdw/L) with E. coli 
BL21 (pGDH1) (30 g cdw/L) led to the recycling of NADPH for 3000 times 
in the bioreduction. Further increase the cell density of E. coli BL21 (pGDH1) 
to 40 g cdw/L resulted in a slight increase of the TTN from 3000 to 3200. 
Instead, increase of the reduction enzyme has more influence on the cofactor 
TTN: bioreduction of 3-ketoester 1 with 30 g cdw/L of B. pumilus Phe-C3 and 
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30 g cdw/L of E. coli BL21 (pGDH1) afforded a TTN of 3700 for the 
recycling of NADPH. 
Finally, the permeabilized cells of E. coli BL21 (pGDH1) with an activity of 
61 U/g cdw, prepared by the treatment with 10 mM EDTA containing 1% 
toluene, was used for the coupled permeabilized cells approach. Since these 
cells have very high activity for NADPH recycling, they were used in 20 g 
cdw/L to couple with 40 g cdw/L of B. pumilus Phe-C3 for the bioreduction of 
3-ketoester 1. With initial addition of NADP+ (0.005 mM) and glucose (440 
mM), bioreduction for 34 h gave a TTN of 4200 for NADPH recycling. 
 
Table 3.2. Coupled permeabilized cells of B. pumilus Phe-C3 and a cofactor-regenerating 
microorganism for bioreduction of ethyl 3-keto-4, 4, 4-triflurobutyrate 1 with NADPH 
recycling 
 


























1 60+60 0.005 440 20 40 - - 43 8.0 1600 
2 60+60  0.005 440 20 - 40 - 43 15.5 3100 
3 60+60  0.005 440 20 - - 30g 39 15.0 3000 
4 60+60  0.005 440 20 - - 40g 39 16.0 3200 
5 60+60 0.005 440 30 - - 30g 39 17.5 3700 
6 60+60 0.005 440 40 - - 20h 34 21.0 4200 
7 60+60 0.001 440 40 - - 20h 34 25.0 2500 
a) 3-ketoester 1 was added at beginning (60 mM) and at 5 h (60 mM).  
b) More glucose (1.5-2.0 M) was supplied during the reaction.  
c) B. pumilus Phe-C3.  
d) B. subtilis BGSC 1A1.  
e) E. coli XL-1 Blue (pGDH1).  
f) E. coli BL21 (pGDH1).  
g) Permeabilized cells with an activity of 24 U/g cdw.  
h) Permeabilized cells with an activity of 61 U/g cdw. 
 
The more active permeabilized cells of E. coli recombinant are suitable 
catalysts for the recycling of NADPH as well as NADH. In addition, they 
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contain no NADPH/ANDH oxidase activity. With permeabilized cells of B. 
subtilis BGSC 1A1 as the cofactor-recycling microorganism, a TTN of 1600 
was achieved for bioreduction of 3-ketoester 1 with the initial addition of 0.01 
mM NADP+.63 The TTN could not be increased by adding a reduced amount 
of cofactor, such as 0.005 mM NADP+ (Table 3.2). It was, however, 
significantly increased to 3100 by using E.coli XL-1 Blue (pGDH1) with an 
activity of 14 U/g cdw to replace the wide-type strain. Further increase the 
GDH activity by using even more active cells of E. coli BL21 (pGDH1) did 
not increase too much the TTN (entry 4, Table 3.2). Obviously, the limiting 
factor here is the inefficiency of the reducing-microorganism. Increase of the 
cell density of B. pumilus Phe-C3 to 40 g cdw/L and coupling with E. coli 
BL21 (pGDH1) (20 g cdw/L) with an activity of 61 U/g cdw led to the 
increase of NADPH recycling to 4200 times. This is very significant 
improvement of the cofactor TTN for the coupled permeabilized cells 
approach: considering the price of NADP+ of 6-7 EUR/g, recycling of 
NADPH for 4200 significantly reduced the cofactor cost and made the 
process in the practical range for producing final chemicals and 
pharmaceutical intermediates. The high TTN achieved for the bioreduction of 
3-ketoester 1 with two permeabilized cells approach is similar to the TTN 
obtained for the same reduction with a single permeabilized microorganism 
with two necessary enzymes.148 This indicates that the cofactor can easily 
across between the two permeabilized microbial cells and provides the same 
catalytic efficiency as it was in the single permeabilized cell. In current 
system, NADP+ was used at 0.005 mM that is far below the Km. Increase of 


























of NADPH. However, the rate of the reduction was only slightly increased (21 
vs. 25 mM product for entry 6 vs. 7, Table 3.2), and the TTN of the cofactor 
recycling was significantly reduced.  This is mainly due to the low activity of 
the reductase-containing microorganism. Thus, the system could be further 
improved by using a highly active reducing microorganism. 
 
3.3.5 Long-term bioreduction of 3-ketoester 1 with efficient NADPH 
recycling by the coupled permeabilized cells approach with the addition 
of NADP+ for multiple times 
 
Bioreduction of 60 mM 3-ketoester 1 with permeabilized cells of B. pumilus 
Phe-C3 (40 g cdw/L) and E. coli BL21 (pGDH1) (20 g cdw/L) was performed 
for 68 h with three times addition of 0.005 mM NADP+. As shown in Figure 
3.4, the reaction rate was high at beginning and produced 16.5 mM of 3-




















Figure 3.4. Product formation in bioreduction of ethyl 3-keto-4,4,4-triflurobutyrate 1 by using 
coupled permeabilized cells with the addition of 0.005 mM NADP+ at different time points. B. 
pumilus Phe-C3 (40 g cdw/L) and E. coli BL21 (pGDH1) (20 g cdw/L; activity: 61 U/g cdw) 




Table 3.3. Product formation in bioreduction of ethyl 3-keto-4,4,4-triflurobutyrate 1 with 
coupled permeabilized cells 
 
























1 40 20 60 440 1.3 0 0.005    
      20 +0.005 19.0 32 3800 
      44 +0.005 36.0 60 3600 
      68  50.5 84 3400 
2 40 20 60+60c 440 1.3 0 0.005    
      24 +0.005 20.0 17 4000 
      48 +0.005 38.0 31 3800 
      72 +0.005 52.5 44 3500 
      96  64.0 53 3200 
a) Permeabilized E. coli BL21 (pGDH1) cells with an activity of 61 U/g cdw.  
b) Activity was determined over the first 1h.  
c) 3-ketoester 1 was added at beginning (60 mM) and at 5 h (60 mM).             
 
became lower, which may have been due to decomposition of the cofactor, 
since the half-life of NADPH in the buffer was 24 h.148 Nevertheless, the 
product concentration reached 19.0 mM in the first cycle with a TTN of 3800. 
The addition of another 0.005 mM NADP+ at 20 h resulted in a fast conversion 
of 3-ketoester 1 to 3-hydroxyester (R)-2. The phenomena in the second and 
third cycle are similar to the first one. As listed in Table 3.3, the 3-
hydroxyester (R)-2 was formed in 36.0 mM with an overall cofactor TTN of 
3600 at 44 h and in 50.5 mM and 95% ee (R) with an overall TTN of 3400 and 
84% conversion at 68 h. This is a very good result. In a comparison 
experiment, bioreduction of 60 mM 3-ketoester 1 with the resting cells of B. 
pumilus Phe-C3 (40 g cdw/L) for 25 h resulted in only 20.5 mM (R)-2 with 
34% conversion. In another experiment, bioreduction was performed with 120 
mM of 3-ketoester 1 for 96 h with four times addition of 0.005 mM NADP+. 
Figure 2.4 gave nearly the same curves for two cases within the first 68 h. The 
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3-hydroxyester (R)-2 was formed in 52.5 mM with an overall TTN of 3500 at 
72 h. The addition of 0.005 mM NADP+ at this time point accelerated again 
the bioreductions, and the product concentration reached 64.0 mM at 96 h with 
an overall TTN of 3200.  
 
3.4 Summary and Conclusions 
 
In conclusion, the GDH of B. subtilis BGSC 1A1 was cloned and functionally 
expressed in E. coli BL21 (pGDH1), showing an activity of 170 U/g protein. 
The recombinant strain was successfully permeabilized with EDTA/toluene to 
give an activity of 61 U/g cdw for NADPH recycling. Such permeabilized 
cells demonstrated much higher GDH activity and no NADPH or NADH 
oxidase activity, being advantageous over the wild-type strain. They were 
suitable for the recycling of both NADPH and NADH. Coupling of 
permeabilized cells of B. pumilus Phe-C3 and E. coli BL21 (pGDH1) for the 
reduction of ethyl 3-keto-4-triflurobutyrate 1 gave a TTN of 4200 for NADPH 
recycling, which is 2.6 times of the TTN obtained by using B. subtilis BGSC 
1A1. The high TTN value is in the practical range for the synthesis of fine 
chemicals. Bioreduction of 3-ketoester 1 via coupled permeabilized cells with 
the addition of 0.005 mM NADP+ for 3 times gave 50.5 mM of 3-
hydroxyester (R)-2 in 95% ee and 84% conversion with an overall TTN of 
3400 for NADPH recycling. These results demonstrated the high stability and 
productivity of the new biocatalysts system and a practical synthesis of (R)-
ethyl 3-hydroxy-4-trifluorobutanoate 2. Our method could be applicable to 












REGIO- AND STEREO-SELECTIVE 
BIOHYDROXYLATIONS WITH A 
RECOMBINANT ESCHERICHIA COLI 
EXPRESSING P450PYR MONOOXYGENASE 













Regio- and stereo-selective hydroxylations are useful reactions for the 
preparation of chiral alcohols that are valuable fine chemicals, pharmaceutical 
intermediates, and flavors and fragrances. However, this type of 
transformations remains as a great challenge in classical chemistry.172-177 On 
the other hand, hydroxylation can be achieved by using an enzyme such as a 
monooxygenase which catalyzes the insertion of one O atom of molecular 
oxygen into a specific C-H bond. 5,105,178-185 In addition to the high regio- and 
stereo-selectivity, biohydroxylation utilizes molecule oxygen as oxidant, thus 
being an ideal tool for green oxidation and sustainable chemical synthesis. 
Some progress has been made in the discovery and application of appropriate 
monooxygenases for biohydroxylations, 5,105,178-185 and several enzymatic 
systems have been extensively investigated, such as methane monooxygenase 
(MMO),186,187 membrane-bound alkane hydroxylase (alkB),188-190 and 
cytochrome P450 monooxygenases.25-44 Among them, cytochrome P450 
monooxygenases are of great interest, due to their wide existence in nature and 
high diversity. Many P450 monooxygenases from wild-type strains were 
identified for biohydroxylations,30,31 and some of them, such as P450cam and 
P450BM-3, have been characterized,25-27 cloned and expressed,32-36 and 
engineered via directed evolution24,37-41 or protein engineering42-44. However, it 
is still difficult to obtain appropriate P450 monooxygenase with desired 
substrate specificity and high selectivity for a given hydroxylation. It is also a 
significant challenge to construct highly active recombinant biocatalysts via 
genetic engineering of P450 monooxygenase, possibly due to the particular 
complicacy of P450 enzyme and system. 
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Previously, we discovered Sphingomonas sp. HXN-20064 containing a P450pyr 
monooxygenase as a powerful biohydroxylation catalyst with unique substrate 
specificity and range as well as high selectivity. The wild-type strain was 
shown to be the best catalyst known thus far for the hydroxylation of a range 
of alicyclic substrates such as N-substituted pyrrolidines,65 pyrrolidinones,66 
piperidines,67 piperidinones,68 and azetidines,67 with high activity and good to 
excellent regio- and stereo-selectivity. For example, hydroxylation of N-
benzyl-pyrrolidin-2-one 1 with this strain gave N-benzyl-4-hydroxypyrrolidin-
2-one 2 in >99% ee,66 a useful intermediate for the preparation of an oral 
carbapenem antibiotic CS-83469 and nootropic drug (S)-Oxiracetame.191 A 
Pseudomonas putida strain expressing P450pyr monooxygenase was 
constructed,69 but the hydroxylation activity was rather low. Both the wild-
type strain and the P. putida recombinant need to grow on n-octane, which is a 
flammable and relatively expensive substrate, thus being a technical challenge 
in large-scale application. 
We aim to engineer a recombinant E. coli strain expressing P450pyr 
monooxygenase with high whole-cell hydroxylation activity, no side reaction, 
and easy growth on non-flammable substrate, and then employ this 













Ampicillin (>99%), kanamycin solution (50 mg/mL), NADH (>99%), N-
benzyl pyrrolidine-2-one 1 (98%), (-)-!-pinene ("99%) 5, norbornane 7 (98%), 
tetralin 9 (99%), (-)-trans-pinocarveol ("96%), exo-norborneol 8 (98%), endo-
norborneol (96%), and DL-dithiothreitol ("99%) were purchased from Sigma-
Aldrich. 2-Tetralol 10 (97%) was obtained from Acros Organics. 6-Methoxy-
2-tetralol (>96%) was purchased from JW-Pharmlab. 6-Methoxy-1-tetralol 
(98%) and 7-methoxy-1-tetralol (98%) were bought from Aurora Building 
Blocks. Isopropyl !-D-thiogalactopyranoside (ITPG, >99%) was bought from 
1st BASE. 6-Methoxy-tetralin 11 (85%, sigma) was further purified by 
column chromatography on silica gel (Rf = 0.32, n-hexane/ethyl acetate 40:1) 
to purity >98% (GC). N-benzyloxycarbonyl pyrrolidine 365 was prepared 
according to the published procedures. 
 
4.2.2 Strain and biochemicals 
 
Escherichia coli BL21 (DE3), DH5#, plasmids pETDuet and pRSFDuet were 
purchased from Novagen. Failsafe PCR 2X Premix G was purchased from 
Epicentre Biotechnologies. Phusion DNA polymerase, T4 DNA ligase and the 
restriction enzymes NcoI, NdeI, KpnI, and AflII were purchased from New 
England Biolabs. Medium components tryptone and yeast extract were 
purchased from Biomed Diagnostics. 
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4.2.3 Analytical methods 
 
The concentrations of N-benzyl pyrrolidine-2-one 1, N-benzyl-4-hydroxy-
pyrrolidin-2-one 2, N-benzyloxycarbonyl pyrrolidine 3 and N-
benzyloxycarbonyl-3-hydroxypyrrolidine 4 were analyzed by Shimadzu 
Prominence HPLC on a Hypersil BDS-C18 column (125 mm $ 4 mm) at 25 
ºC. UV detection: 210 nm; flow rate: 1 mL/min. Eluent: acetonitrile/water 
(20:80); retention time: 2.8 min for N-benzyl-4-hydroxy-pyrrolidin-2-one 2, 
and 7.8 min for N-benzyl pyrrolidine-2-one 1. Eluent: acetonitrile/water 
(25:75); retention time: 4.7 min for N-benzyloxycarbonyl-3-
hydroxypyrrolidine 3, and 11.4 min for N-benzyloxycarbonyl pyrrolidine 4. 
The ee of N-benzyl-4-hydroxy-pyrrolidin-2-one 2 and N-benzyloxycarbonyl-
3-hydroxypyrrolidine 4 were determined by Shimadzu Prominence HPLC on a 
Chiralpak AS-H column (150 mm $ 2.1 mm) at 25 ºC. UV detection: 210 nm; 
flow rate: 1 mL/min. Eluent: n-hexane/2-propanol (4:1); retention time: 20.3 
min for (S)-N-benzyl-4-hydroxy-pyrrolidin-2-one 2, and 30.5 min for (R)-N-
benzyl-4-hydroxy-pyrrolidin-2-one 2. Eluent: n-hexane/2-propanol (10:1); 
retention time: 13.5 min for (S)-N-benzyloxycarbonyl-3-hydroxypyrrolidine 4, 
and 15.4 min for (R)-N-benzyloxycarbonyl-3-hydroxypyrrolidine 4. 
The concentrations of (-)-!-pinene 5, trans-pinocarveol 6, norbornane 7, exo-
norbornaneol 8, tetralin 9, 2-tetralol 10, 6-methoxy-tetralin 11, 7-methoxy-2-
tetralol 12 and their corresponding products were analyzed by Agilent GC 
6890 on an Agilent HP-5 column (25 m $ 0.32 mm) with inlet temperature of 
280 ºC and detector temperature of 300 ºC. Temperature program: 60 ºC 
increase to 100 ºC at a rate of 5 ºC/min, increase to 116 ºC at a rate of 2 
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ºC/min, keep 2 min, then increase to 280 ºC at a rate of 30 ºC/min, and keep 
for 3 min. Retention time: 4.2 min for norbornane 7, 7.8 min for exo-
norborneol 8, 7.9 min for (-)-!-pinene 5, 8.0 min for endo-norborneol, 12.6 
min for trans-pinocarveol 6, 13.5 min for tetralin 9, 19.9 min for 1-tetralol, 
20.4 min for 2-tetralol 10, 20.9 min for 6-methoxy-tetralin 11, 21.1 min for 7-
methoxy-1-tetralol, 21.3 min for 7-methoxy-2-tetralol 12, 22.3 min for n-
hexadecane (internal standard), 22.5 min for 6-methoxy-1-tetralol and 22.8 
min for 6-methoxy-2-tetralol. 
 
4.2.4 Genetic engineering of E. coli BL21-pRSFDuet P450pyr-pETDuet 
Fdx FdR1500 [E. coli (P450pyr)] 
 
Plasmid pCom8-PA7F200R150069 was used as a PCR template to amplify the 
coding region of cytochrome P450pyr (PA7), ferredoxin (F200), and ferredoxin 
reductase (R1500). The P450pyr gene was amplified using the forward primer 
P450fwd (5’ TTA ACT ACT CCA TGG AAC ATA CAG GAC AAA GCG 
CGG 3’, the NcoI restriction site is underlined) and reverse primer P450rev 
(5’ TTA ACT ACT GGT ACC CTA CGC GTG GAC GCG AAC 3’, the KpnI 
restriction site is underlined). The F200 gene was amplified using the forward 
primer Frdxfwd (5’ TTA ACT ACT CCA TGG ca ACA GTG ACC TAT GTT 
GAA ATA AAT GGC AC 3’, the NcoI restriction site is underlined, the 
second codon of the F200 gene, in small caps, was changed from the original 
cca to gca) and reverse primer Frdxrev (5’ TTA ACT ACT CTT AAG TCA 
ATG CTG CGC GAG AGG AAG 3’, the AflII restriction site is underlined). 
The R1500 gene was amplified using the forward primer R1500fwd (5’ TTA 
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ACT ACT CAT ATG ATC CAC ACC GGC GTG AC 3’, the NdeI restriction 
site is underlined) and the reverse primer R1500rev (5’ TTA ACT ACT GGT 
ACC TTA GAG GGA GGT TGG GGA CG 3’, the KpnI restriction site is 
underlined). PCR amplified genes were digested with their respective enzymes. 
The digested P450pyr fragment was ligated into the pRSFDuet vector that was 
digested with NcoI and KpnI restriction enzymes. The digested F200 fragment 
was ligated into the multiple cloning site (MCS) 1 of the pETDuet vector that 
was digested with NcoI and AflII. The resulting plasmids from the ligations 
were separately transformed into chemical competent E. coli DH5# cells 
which were then plated on Luria-Bertani (LB) agar plates containing 50 
µg/mL kanamycin (for pRSFDuet P450pyr) and 100 µg/mL ampicillin (for 
pETDuet F200) respectively. Subsequently, the digested R1500 fragment was 
ligated into the MCS 2 of the same pETDuet vector, containing the F200 gene, 
digested with NdeI and KpnI restriction enzymes. The resulting plasmid from 
the ligation was transformed into chemical competent E. coli DH5# cells, 
which were then plated on LB agar plates containing 100 µg/mL ampicillin. 
Finally, the purified pRSFDuet P450pyr and pETDuet F200 plasmids were 
transformed into electrocompetent E. coli BL21 (DE3) and plated on LB agar 
plates containing 50 µg/mL kanamycin and 100 µg/mL ampicillin. 
 
4.2.5 Growth and specific hydroxylation activity of E. coli (P450pyr)  
 
The recombinant E. coli (P450pyr) was inoculated on LB agar plate (10 g 
tryptone, 5 g yeast extract and 5 g NaCl in 1 L deionized water with 2% agar) 
containing ampicillin (100 µg/mL) and kanamycin (50 µg/mL), and grown 
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overnight at 37 ºC. A single colony from the LB agar plate was inoculated into 
30 mL of LB medium containing ampicillin (100 µg/mL) and kanamycin (50 
µg/mL), and grown at 300 rpm and 37 ºC for 12 h, giving an OD600 of 4.0 
(1.6 g cdw/L). 
To obtain high specific hydroxylation activity of this recombinant strain, 
induction conditions were optimized, including induction time points (1.5 to 
2.5 h after inoculation), induction durations (2 to 6 h), induction amounts (0.3 
to 1.0 mM IPTG), and induction temperatures (25 to 37 ºC). The optimum 
culture procedure was the followings: 2 mL of the above preculture was added 
in 100 mL LB medium containing ampicillin (100 µg/mL) and kanamycin (50 
µg/mL), and the mixture was shaken at 300 rpm and 37 ºC. IPTG (0.5 mM) 
was added when OD600 reached 1.5 (0.6 g cdw/L) at 2 h, the temperature was 
changed to 30 ºC, and the mixture was shaken at 300 rpm for another 3 h. 
Samples were taken at different time points for OD measurement, activity test, 
and CFE preparation. The cells were harvested at the late exponential phase 
with an OD600 of 4.0 (1.6 g cdw/L) by centrifugation at 10,375 g for 10 min 
and the cells were directly used for the activity test and biotransformation. 
To test the specific hydroxylation activity of the recombinant strain, the above 
freshly harvested cells were resuspended in KP buffer (50 mM; pH = 7.5) to 
obtain a density of 1.5 g cdw/L. To 950 µL of the cell suspension was added 
40 µL of glucose stock solution (50%, w/v), 10 µL of N-benzyl pyrrolidine-2-
one 1 or N-benzyloxycarbonyl pyrrolidine 3 stock solution (0.2 M in 
methanol) to a final volume of 1 mL in a 2 mL Eppendorf tube. The mixture 
was shaken at 1200 rpm and 30 ºC with a Bioer mixing block MB-102 for 30 
min, and then 1 mL cold methanol was added to quench the reaction. Analytic 
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sample was prepared by violent vortex and centrifugation of the reaction 
mixture. Reverse phase HPLC was used to determine the product 2 or 4 
concentration. The specific hydroxylation activity was expressed in U/g cdw, 
and 1 U was defined as the formation of 1 µmol product/min. 
 
4.2.6 Protein gel and CO difference spectrum of CFE of E. coli (P450pyr)  
 
5 mL cell suspension (10 g cdw/L) of above freshly harvested cells in KP 
buffer (50 mM; pH = 7.5) was passed through a homogenizer (Constant Cell 
Disruption System) twice at 20 kpsi. The cell debris was removed by 
centrifugation at 13,000 g at 4 ºC for 30 min. The supernatant was diluted 10 
times with KP buffer (50 mM; pH = 7.5), and the protein concentration was 
determined by Bradford protein content assay139 with bovine serum albumin 
(BSA) as standard. 
SDS-PAGE was performed by loading 15 µg CFE on a gel containing 0.1% 
sodium dodecyl sulfate and 14% acrylamide, staining with a 0.1% solution of 
Commassie brilliant blue R-250 in methanol/acetic acid/water (4:1:5; v/v/v), 
and destaining by soaking in deionized water overnight. 
The CO difference spectrum of P450pyr expressed in E. coli (P450pyr) was 
measured at room temperature (25 ºC) in a Hitachi UV-Vis ratio beam 
spectrophotometer U-1900, with the use of quartz cuvette with a 1 cm light 
path. 3 mL CFE (1.7 g protein/L) in KP buffer (50 mM; pH = 7.5) in the 
quartz cuvette was reduced by addition of a few milligrams of solid 
dithiothreitol and saturated with CO by bubbling the gas for about 2 min. The 
UV absorbance at 450 nm of CFE was measured before and after the CO 
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bubbling. A value of 91 cm-1 for the molar extinction increment at 450 nm for 
cytochrome P450pyr was used to calculate the P450pyr concentration.192 
 
4.2.7 Optimization of biohydroxylation of N-benzyl pyrrolidine-2-one 1 
with E. coli (P450pyr)  
 
To find out the optimal pH condition for biohydroxylation of N-benzyl 
pyrrolidine-2-one 1, 400 µL of glucose stock solution (50%, w/v) and 10 mM 
N-benzyl pyrrolidine-2-one 1 (17.5 mg, 0.1 mmol) were added to suspensions 
containing freshly harvested cells (5 g cdw/L) in 10 mL KP buffer (50 mM; 
pH = 6.0 to 8.0) or 10 mL Tris-HCl buffer (50 mM; pH = 8.5 to 8.9). The 
mixtures were shaken at 300 rpm and 25 ºC. Aliquots (100 µL) were taken out 
at 30 min and mixed with cold methanol (100 µL), and the cells were removed 
by centrifugation. The supernatants were analyzed by reverse phase HPLC to 
determine the product 2 concentrations. 
To find out the optimal temperature condition for biohydroxylation of N-
benzyl pyrrolidine-2-one 1, 400 µL of glucose stock solution (50%, w/v) and 
10 mM N-benzyl pyrrolidine-2-one 1 (17.5 mg, 0.1 mmol) were added to 
suspensions containing freshly harvested cells (5 g cdw/L) in 10 mL KP buffer 
(50 mM; pH = 8.0). The mixtures were shaken at 300 rpm and 20 ºC to 35 ºC 
for 30 min. Analytic samples were prepared using the same method described 





4.2.8 Kinetic constants of biohydroxylation of N-benzyl pyrrolidine-2-one 
1 and N-benzyloxycarbonyl pyrrolidine 3 with CFE or resting cells of E. 
coli (P450pyr) 
 
To 925 to 933 µL of the CFE (1.5 g protein/L) in KP buffer (50 mM; pH = 
8.0), 40 µL of glucose stock solution (50%, w/v), 25 µL of NADH stock 
solution (0.2 M), and 2 to 10 µL of N-benzyl pyrrolidine-2-one 1 or N-
benzyloxycarbonyl pyrrolidine 3 stock solution (0.2 M or 0.5 M in methanol) 
were added to a final volume of 1 mL in a 2 mL Eppendorf tube. The mixtures 
were shaken at 1,200 rpm and 25 ºC with a Bioer mixing block MB-102 for 15 
min, and then 1 mL cold methanol was added to quench the reaction. Analytic 
samples were prepared using the same method described above, and analyzed 
by HPLC. The initial velocities were calculated from the product 2 and 4 
formed within the first 15 min, and they were used to plot 1/[v] vs. 1/[S].171 
Freshly harvested cells were resuspended in KP buffer (50 mM; pH = 8.0) to 
obtain a density of 1.5 g cdw/L. To 950 to 958 µL of the cell suspensions were 
added 40 µL of glucose stock solution (50%, w/v) and 2 to 10 µL of N-benzyl 
pyrrolidine-2-one 1 or N-benzyloxycarbonyl pyrrolidine 3 stock solution (0.2 
M or 0.5 M in methanol) to a final volume of 1 mL in a 2 mL Eppendorf tube. 
The initial velocities were calculated by the method described above and then 






4.2.9 General procedure for the biohydroxylation of N-benzyl pyrrolidine-
2-one 1 to N-benzyl-4-hydroxy-pyrrolidin-2-one 2 with resting cells of E. 
coli (P450pyr) 
 
To suspensions containing freshly harvested cells (5 g cdw/L) in 10 mL KP 
buffer (50 mM; pH = 8.0) were added 400 µL of glucose stock solution (50%, 
w/v) and 5 mM (8.8 mg, 0.05 mmol) to 25 mM (43.8 mg, 0.25 mmol) N-
benzyl pyrrolidine-2- one 1. The mixture was shaken at 25 ºC and 300 rpm. 
Appropriate amount of 1.0 M NaOH solution was added at several time points 
to keep pH value of the reaction system around 8.0. At different time points, 
analytic samples were prepared using the same method described above, and 
analyzed by HPLC. 
 
4.2.10 General procedure for the biohydroxylation of (-)-!-pinene 5 to 
(1R)-trans-pinocarveol 6 with resting cells of E. coli (P450pyr) 
 
For volatile substrates (-)-!-pinene 5, biotransformations were carried out in 
close systems. To 5 different 100 mL shaking flasks containing 10 mL cell 
suspensions (5 to 10 g cdw/L) in KP buffer (50 mM; pH = 8.0) were added 
400 µL of glucose stock solution (50%, w/v) and 5 mM (6.8 mg, 0.05 mmol) 
to 10 mM (13.6 mg, 0.1 mmol) (-)-!-pinene 5. Then the flasks were covered 
with glass stoppers and tightly sealed with parafilm. The mixtures were shaken 
at 300 rpm and 25 ºC. The flasks were removed from the shaker at different 
time point, put into ice for 10 min, opened, and mixed with same volume ethyl 
acetate containing 2 mM n-hexadecane. The flask was kept on ice for another 
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10 min, mixed violently on vortex, and then the organic phase was separated, 
dried over anhydrous Na2SO4, and used for GC analysis. 
 
4.2.11 General procedure for the biohydroxylation of norbornane 7, 
tetralin 9, and 6-methoxy-tetralin 11 with E. coli (P450pyr) 
 
The biotransformation of norbornane 7 at 5 mM (4.8 mg, 0.05 mmol) to 60 
mM (57.6 mg, 0.6 mmol) was performed according to the same procedure for 
the hydroxylation of (-)-!-pinene 5 described above. 
To suspensions containing freshly harvested cells (5 to 10 g cdw/L) in 10 mL 
KP buffer (50 mM; pH = 8.0) were added 400 µL of glucose stock solution 
(50%, w/v) and 5 mM (6.6 mg, 0.05 mmol) to 10 mM (13.2 mg, 0.1 mmol) 
tetralin 9 or 5 mM (8.1 mg, 0.05 mmol) to 10 mM (16.2 mg, 0.1 mmol) 6-
methoxy-tetralin 11. The mixtures were shaken at 300 rpm and 25 ºC. 
Aliquots (200 µL) were taken out at different time points and extracted with 
200 µL ethyl acetate containing 2 mM n-hexadecane as internal standard. All 
the supernatants were separated, and dried over anhydrous Na2SO4, and the 
















4.3 Results and Discussion 
 
4.3.1 Genetic engineering, cell growth, and protein expression of E. coli 
(P450pyr) 
 
To engineer an active recombinant P450pyr, plasmid pCom8-PA7F200R150069 
was used as a polymerase chain reaction (PCR) template to amplify the coding 
region of cytochrome P450pyr (PA7), ferredoxin (F200, Fdx), and ferredoxin 
reductase (R1500, FdR). PCR amplified genes were digested with their 
respective enzymes. The digested P450pyr fragment was ligated into the 
pRSFDuet, while the digested Fdx fragment was ligated into the pETDuet 
vector, and the resulting plasmids from the ligations were separately 
transformed into chemical competent E. coli DH5# cells. Subsequently, the 
digested FdR fragment was ligated into the same pETDuet vector containing 
the Fdx gene. The resulting plasmid from the ligation was transformed into 
chemical competent E. coli DH5#. Finally, the purified pRSFDuet P450pyr and 
pETDuet FdxFdR plasmids were transformed into electrocompetent E. coli 
BL21 (DE3). 
The constructed recombinant strain, E. coli (P450pyr), was grown on LB 
medium containing ampicillin (100 µg/mL) and kanamycin (50 µg/mL) at 37 
ºC, and its P450 monooxygenase expression was induced by the addition of 
IPTG after the lag phase. The optimum induction condition was the 
followings: addition of IPTG (0.5 mM) at 2 h and then incubation at 30 ºC for 
3 h. The typical growth curve under the optimal culture condition is shown in 
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Figure 4.2. SDS-PAGE of CFE of E. coli (P450pyr). non-induced (lane 1), induced with IPTG 
for 2 h (lane 2), 3 h (lane 3), 4 h (lane 4), and 5 h (lane 5). 
 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of 
the cell free extracts (CFEs) of E. coli (P450pyr), that was non-induced or 
induced for 2-5 h, was shown in Figure 4.2. Although P450pyr and FdR have 
the similar molecular weight and pI and thus cannot be distinguished in SDS-
PAGE, it was clear that P450pyr/FdR and Fdx were expressed in induced E. 




















































To examine the percentage of the active P450pyr among all the soluble proteins 
of IPTG-induced E. coli (P450pyr), CO difference spectra192 were measured 
with CFEs (1.7 g protein/L) in KP buffer (50 mM; pH = 7.5) at 450 nm. As 
shown in Figure 4.3, UV absorption difference at 450 nm between the CO-
bound reduced P450pyr and reduced P450pyr was 0.041. The active P450pyr 
enzyme in the CFE was thus established as 0.033 g protein/L based on the 
molar extinction increment at 450 nm of 91 cm-1 for P450 enzyme192 This 
corresponds to 1.92% of all soluble proteins in CFEs of E. coli (P450pyr). For 
CFE of non-induced E. coli cells, there was no UV absorption difference at 










Figure 4.3. CO difference spectra of CFEs of E. coli (P450pyr): (() non-induced; (---) induced 
with IPTG for 3 h. 
 
4.3.2 Biohydroxylation of N-benzyl pyrrolidine-2-one 1 and N-
benzyloxycarbonyl pyrrolidine 3 with E. coli (P450pyr) 
 
During cell growth shown in Figure 4.1, the specific hydroxylation activity of 
cells at different time points was measured by taking cell culture and 
















(KP) buffer containing 2% glucose and 2 mM N-benzyl pyrrolidine-2-one 1 or 
N-benzyloxycarbonyl pyrrolidine 3, incubating at 30 ºC for 30 min, and finally 
analyzing the formation of 2 or 4 by HPLC. As shown in Figure 4.1, the 
highest specific hydroxylation activity was 3.8 U/g cdw for substrate 1 and 9.9 
U/g cdw for substrate 3, both with cells taken at 5 h. At this time point, cell 
growth reached late exponential phase. The high hydroxylation activities of E. 
coli (P450pyr) demonstrated that the cloned and expressed P450pyr in the 
recombinant was catalytically functional. These activities are nearly as high as 
those achieved with wild-type Sphingomonas sp. HXN-200 grown on n-octane 
vapor,66 and the cells of the recombinant was much more easily and 
economically prepared than the wild-type strain. Moreover, the specific 
hydroxylation activities are also outstanding in comparison with other well-
known recombinant P450: P. Putida GPo12 (pGEc47!B) (pCom8-PFR1500) 
showed 3 U/g cdw for the hydroxylation of L-limonene,193 while E. coli 
JM103 (pUC13 BM3-1)194 and E. coli BL21 (DE3) (pETDuet-
P450cam/Pdx)(pACYCDuet-PdR/GLD)195 gave 2.4 U/g cdw and 0.05 U/g 
cdw for the hydroxylation of myristate and camphor, respectively, calculated 
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Scheme 4.1 Biohydroxylation of N-benzyl pyrrolidine-2-one 1 and N-benzyloxycarbonyl 




The biohydroxylation of 1 with the recombinant E. coli strain was examined at 
different pH and temperature. pH of 8.0 and 25 ºC were found to be the 
optimum, giving biohydroxylation activity of 4.1 U/g cdw. 
 


















From 1 to 2 CFE 1.5 b) 2.5 11 4.4 
From 1 to 2 Cells 1.5 c) 2.7 5.1 1.9 
From 3 to 4 CFE 1.5 b) 0.99 19 19 
From 3 to 4 Cells 1.5 c) 1.1 11 10 
a) Biohydroxylation was performed with 0.2 to 5.0 mM substrate (1 or 3), 2% (w/v) glucose, 5 
mM NADH, and  1.5 g protein/L CFE or 1.5 g cdw/L cell suspension in 1 mL KP buffer (50 
mM; pH 8.0) at 25 ºC for 15 min, and product formation was determined by HPLC. 
b) g protein/L for CFE. 
c) g cdw/L for resting cell suspension. 
 
The kinetics of biohydroxylation of pyrrolidine-2-one 1 and pyrrolidine 3 with 
resting cells and CFE of E. coli (P450pyr) was investigated, respectively. A set 
of activity assays were performed with substrate 1 and 3 at different 
concentrations in the CFE (1.5 g protein/L) or cell suspensions (1.5 g cdw/L) 
in KP buffer (50 mM; pH = 8.0) containing glucose (2%, w/v) at 25 ºC for 15 
min. The initial velocities at different substrate concentration were used to 
give the plot of 1/[v] vs. 1/[S],171 and the apparent Km and apparent Vmax were 
obtained from the plot. The kinetic data were summarized in Table 4.1. For 
either substrate, the apparent Km for CFE was nearly the same as that for 
resting cells, suggesting that there are nearly no barrier for substrate 1 or 3 to 
cross the cell membrane. Since 1 g cdw contains ca. 0.5 g protein, the apparent 
Vmax based on the protein amount for resting cells is nearly the same as that for 
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CFE for either hydroxylation. Thus, resting cells showed nearly the same 
catalytic efficiency as CFE for these hydroxylations. The catalytic efficiency 
(Vmax/Km) of hydroxylation of pyrrolidine 3 is about 5 times higher than that 
for the hydroxylation of pyrrolidin-2-one 1, with either resting cells or CFE as 
catalysts.  This was the result of the lower Km and higher Vmax values of 
substrate 3. 
 
4.3.3 Preparation of (S)-N-benzyl-4-hydroxy-pyrrolidin-2-one 2 by 
biohydroxylation of N-benzyl pyrrolidine-2-one 1 with E. coli (P450pyr) 
 
To explore the potential of using E. coli (P450pyr) for the production of (S)-N-
benzyl-4-hydroxy-pyrrolidin-2-one 2, a set of reactions were performed at 25 
ºC for 25 h with N-benzyl pyrrolidine-2-one 1 as substrate at different 
concentrations and resting cells as biocatalyst (5 g cdw/L) in KP buffer (50 
mM; pH 8.0) containing glucose (2%, w/v). Since the apparent Km of the 
recombinant whole cells for N-benzyl pyrrolidine-2-one 1 was 2.7 mM, 5.0 
mM and higher substrate concentrations were tested for the hydroxylation. As 
shown in Figure 4.4, the reaction rate was high within the first 3 h and 
decreased afterwards for initial substrate concentration of 5 mM. This is 
possibly due to the relatively low substrate concentration in the              
biotransformation mixture after 3 h. Increase of the initial substrate 
concentration to 10, 15, 20, and 25 M led to longer initial period for fast 
conversion and higher final product concentration, In the case of using 15, 20, 
and 25 mM substrates, the reaction rates at the first 6 h were nearly the same, 
since these concentration are much higher than the apparent Km. Afterwards, 
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the biohydroxylation of 25 mM substrate still showed good reaction rate from 
6 h to 21 h, giving (S)-2 in 10.8 mM at 25 h. This is a 2.6 times increase of 
product concentration comparing with the use of wild-type strain (4.08 mM).66 
These results demonstrated also that the recombinant P450pyr monooxygenase 
in E. coli cells is relatively stable, keeps activity for a relatively long period, 
and can survive from high concentration of substrate and product. The 
conversions in these examples amounted to 76%-43%. Nevertheless, higher 
conversion could be achieved by adding smaller portions of substrate at 
different reaction time points instead of adding much more substrate at the 
beginning of biohydroxylation. Currently, we are also investigating the use of 
liquid-liquid biphasic system as well as growing cells as catalyst to further 
improve the productivity for biohydroxylation of N-benzyl pyrrolidine-2-one 1. 



















Figure 4.4. Time course of the formation of (S)-N-benzyl-4-hydroxy-pyrrolidin-2-one 2  in 
biohydroxylation of N-benzyl pyrrolidine-2-one 1 with resting cells of E. coli (P450pyr)  (5 g 
cdw/L) in KP buffer (50 mM; pH 8.0) containing glucose (2%, w/v) at 25 ºC and at different 






4.3.4 Regio- and stereo-selective allylic biohydroxylation of (-)-!-pinene 5 
to (1R)-trans-pinocarveol 6 with E. coli (P450pyr) 
 
OHE. coli (P450pyr)
5 6  
Scheme 4.2 Regio- and stereo-selective allylic biohydroxylation of (-)-!-pinene 5 to (1R)-
trans-pinocarveol 6 with E. coli (P450pyr). 
 
Pinocarveol is a metabolite of !-pinene and is widely used in fragrance and 
flavour industry.196 It is produced by the isolation from essence oils of natural 
sources, but its availability is rather limited. Therefore, the development of 
chemical and enzymatic methods to produce pinocarveol from easily available 
and low-price !-pinene has drawn increasing attention. As chemical methods 
often produce mixtures of different products, the development of green and 
selective enzymatic method is desirable since it may produce pinocarveol in 
high purity and natural identical form. Thus far, only two biocatalytic systems 
have been reported to directly hydroxylate !-pinene into pinocarveol.197,198 
The better result was achieved by biotransformation of (-)-!-pinene 5 with a 
Picea abies suspension culture to give (1R)-trans-pinocarveol 6. However, the 
product concentration was very low and the reaction is slow and not clean: 
only 0.32 mg 6 was formed, together with other products, in 100 mL plant 
culture suspension after 8 days.198 
The recombinant E. coli (P450pyr) turned out to be a good biocatalyst for the 
biohydroxylation of !-pinene 5 to (1R)-trans-pinocarveol 6 with much higher 





Table 4.2. Regio- and stereo-selective hydroxylation of (-)-!-pinene 5 with E. coli (P450pyr) to 
(1R)-trans-pinocarveol 6 
 
a) Biotransformation was performed with substrate 5 in cell suspension of E. coli (P450pyr) in 





Figure 4.5. GC chromatograms of samples taken from biohydroxylation of (-)-!-pinene 5 (5 
mM) in 10 mL cell suspension (10 g cdw/L) in KP buffer (50 mM; pH 8.0) containing glucose 
(2%, w/v) at 300 rpm and 25 ºC . A)  0 min; B) 5 h. 
 
of 5 with resting cells of E. coli (P450pyr) was carried out in shaking flask with glass 
stopper and sealed by parafilm without taking samples during the reaction. Parallel 
experiments were performed with several flasks and stopped at different time points. 
As shown in Table 4.2, hydroxylation of 5 mM !-pinene 5 with 5 g cdw/L of resting 
cells gave 3.4 mM of (1R)-trans-pinocarveol 6 at 5 h, and the specific hydroxylation 
activity was 5.3 U/g cdw within the first 30 min. Further increase the substrate 
concentration to 10 mM did not increase the final product concentration. Instead, 
better result was achieved by incubating 5 mM substrate in a cell suspension of 10 g 
Entrya) Sub 5 conc. Cell density Prod 6 at 5 h  
 (mM) (g cdw/L) Conc. (mM) 
Conv. 
(%) 
1 5.0 5.0 3.4 68 
2 10 5.0 2.9 29 
3 5.0 10 4.1 82 
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cdw/L. 4.1 mM trans-pinocarveol 6 was formed within 5 h, with a yield of 82%. This 
product concentration is over 200 times higher than that obtained with the best 
biocatalyst system known thus far.198 As shown in Figure 4.5, there is only one 
product peak at 12.6 min in the GC chromatogram for the sample taken at 5 h. This 
result demonstrated clean biohydroxylation of !-pinene 5. E. coli (P450pyr) is thus 
definitely much better than any other known catalysts for the biohydroxylation of 
pinene to trans-pinocarveol, regarding the high yield, high product concentration, and 
clean reaction. 
 
4.3.5 Stereoselective biohydroxylation of norbornane 7 to exo-




7 8  
Scheme 4.3 Stereoselective biohydroxylation of norbornane 7 to exo-norbornaneol 8 with E. 
coli (P450pyr). 
 
Both endo- and exo-norbornaneol are high-value compounds. While the 
former is a key synthon for the preparation of novel cannabionoid analogs199 
and potassium-channel openers,200 the latter serves as an intermediate for the 
production of A1 adenosine receptor agonists.201 The synthesis of 
norbornaneol has been widely studied in recent years,202-206 mainly via the 
reduction of 2-norbornanone.202-206 Only iron (###) porphyrin207 and a purified 
liver P450208 were reported with the possibility of direct hydroxylation of the 
cheaper norbornane 7 into norbornaneol, but giving mixtures of endo- and 
exo-norbornaneol and norbornanone. 
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We examined the potential of biohydroxylation of norbornane 7 with E. coli 
(P450pyr). Here again, the biotransformation was performed with resting cells 
in closed system with several parallel shaking flasks. As shown in Table 4.3 
(entry 1), 1.2 mM exo-norbornaneol 8 was formed within 5 h by incubating 5 
mM norbornane 7 in a cell suspension of 5 g cdw/L, with an exo/endo-
selectivity of 95%. When increasing the cell density to 10 g cdw/L (entry 5), 
1.6 mM exo-norbornaneol 8 was obtained with an exo/endo-selectivity of 95%. 
Increasing initial substrate concentration resulted in increase of catalytic 
activity and final product concentration: biohydroxylation of 60 mM 7 (entry 
4) gave a specific activity within the first 30 min of 6.0 U/g cdw and final 
product concentration of 3.2 mM at 5 h. Once again, E. coli (P450pyr) is a 
much better catalyst than any other known catalytic systems for the 
hydroxylation of norbornane 7 to norbornaneol 8, with very good exo/endo-
selectivity. 
 
4.3.6 Regioselective hydroxylation of tetralin 9 and 11 with E. coli 
(P450pyr) to 2- tetralol 10 and 12, respectively 
 
2-Tetralols 10 and 12 are useful synthetic intermediates. For instance, they can 
be used to prepare pharmacologically active 2-aminotetralins which show 
affinity to the melatonin receptor.209 Several synthetic routes have been 
developed via the reduction of 2-tetralone210-212 or cyclialkylation of arylalkyl 
epoxide.213 However, no direct hydroxylation of the easily accessible and 
much cheaper tetralins has been reported for the preparation of 2-tetralols, 
either by chemical or enzymatic methods. 
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Scheme 4.4 Regioselective hydroxylation of tetralin 9 and 11 with E. coli (P450pyr) to 2-
tetralol 10 and 12. 
 
Table 4.3. Selective biohydroxylation of norbornane 7, tetralin 9, and 6-methoxy-tetralin 11 
with E. coli (P450pyr) 
 
 a) Biotransformation was performed with substrate 7, 9 or 11 in cell suspension of E. coli 
(P450pyr) in 10 mL KP buffer (50 mM; pH = 8.0) containing glucose (2%, w/v) at 300 rpm and 
25 ºC for 5 h. 
 b) The exo/endo selectivity was determined with 5 h sample. 
 c) The 2-tetralol/1-tetralol selectivity was determined with 5 h sample. 
 d) The 7-methoxy-2-tetralol/6-methoxy-2-tetralol selectivity was determined with 5 h sample.  
 
 
The recombinant E. coli (P450pyr) was explored for such type of 
hydroxylation. Biohydroxylation of tetralin 9 and 6-methoxy-tetralin 11 
showed very special regio-selectivity at the non-activated carbon atoms. As 
shown in Table 4.3 (entry 6 to 11), 2-tetralols were formed as the major 
product with 83-84% regioselectivity and specific hydroxylation activity of 
Entrya) Sub. Sub. Conc. 
(mM) 
Cell density 
( g cdw/L) Prod. 









1 7 5.0 5.0 8 1.2 24 95b) 
2 7 10 5.0 8 1.9 19 95b) 
3 7 20 5.0 8 3.0 15 95b) 
4 7 5.0 10 8 1.6 32 95b) 
5 9 5.0 5.0 10 1.1 22 84c) 
6 9 10 5.0 10 1.0 10 83c) 
7 9 5.0 10 10 1.7 34 84c) 
8 11 5.0 5.0 12 1.2 24 83d) 
9 11 10 5.0 12 1.2 12 84d) 
10 11 5.0 10 12 2.1 42 83d) 
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5.1 U/g cdw and 7.3 U/g cdw for 2-tetralols 10 and 12, respectively. 
Hydroxylation of 5 mM substrate 9 at the cell density of 10 g cdw/L gave 2-
tetralol 10 in 1.7 mM at 5 h. 2.1 mM 7-methoxy-2 tetralol 12 was formed 
within 5 h by hydroxylation of 5 mM substrate 11 in a cell suspension of 10 g 
cdw/L. In all the cases, no ketone was formed according to GC analysis. The 
identification of bioproduct 10 was straightforward by comparing its retention 
time in GC chromatogram with that of the commercially available standard 10. 
On the other hand, the identification of bioproduct from biohydroxylation of 
6-methoxy-tetralin 11 was difficult, since the desired product 7-methoxy-2-
tetralol 12 is not commercially available, and the hydroxylation may create 
theoretically four different regioisomers. Fortunately, all other three 
regioisomers are available, and they have different retention time in GC 
analysis: 21.1 min for 7-methoxy-1-tetralol, 22.5 min for 6-methoxy-1-tetralol, 
and 22.8 min for 6-methoxy-2-tetralol, respectively. The bioproduct from 
biohydroxylation of 11 has a retention time of 21.3 min, which is different 
from those of the three known isomers, thus it is a different compound. In 
addition, GC-MS analysis of the bioproduct showed a M of 178, 
corresponding to the mass of a hydroxylated 6-methoxy-tetralin. Therefore, 
the structure of the bioproduct was deduced to be 7-methoxy-2-tetralol 12. 
Although the product concentrations and conversions of these 
biohydroxylations are relatively low, our results represent the first example of 
hydroxylation of tetralins on the non-activated carbon atoms at 2-position. 
Further improvement of the productivity of P450pyr for these hydroxylations 




4.4 Summary and Conclusions 
 
We have engineered a recombinant E. coli expressing cytochrome P450pyr 
monooxygenase from Sphingomonas sp. HXN-200, with specific activity of 
4.1 U/g cdw and 9.9 U/g cdw for the hydroxylation of N-benzyl pyrrolidine-2-
one and N-benzyloxycarbonyl pyrrolidine, respectively. E. coli (P450pyr) does 
not require n-octane as the growth substrate, demonstrates the similar high 
hydroxylation activity as the wild-type strain, and shows no side reaction. 
Biohydroxylation of N-benzyl pyrrolidine-2-one with resting cells of E. coli 
(P450pyr) gave 10.8 mM (S)-N-benzyl-4-hydroxy-pyrrolidin-2-one, a 2.6-fold 
increase of the product concentration comparing with the wild-type strain. 
Moreover, hydroxylation of (-)-!-pinene with E. coli (P450pyr) cells showed 
excellent regio- and stereo-selectivity and gave (1R)- trans-pinocarveol in 
82% yield and 4.1 mM, being over 200 times higher than that obtained with 
the best biocatalysts known thus far. E. coli (P450pyr) was also able to 
hydroxylate other types of substrates with unique selectivity: biohydroxylation 
of norbornane gave exo-norbornaeol with exo/endo-selectivity of 95%; tetralin 
and 6-methoxy-tetralin were hydroxylated, for the first time, at the non-
































CHAPTER 5  
GREEN AND SELECTIVE 
TRANSFORMATION OF METHYLENE TO 






















Tandem biocatalysis with multiple biocatalysts in one pot enables multi-step 
sequential reactions in the same mild conditions, thus avoiding the time-
consuming, yield-decreasing, and waste-producing isolation and purification 
of intermediates.150,151,214-216 In the past two decades, the development of 
tandem biocatalysis is regarded as an important direction for sustainable 
chemical and pharmaceutical synthesis.45-53 In nature, it is quite common that 
microbial cells containing multiple enzymes can uptake and metabolize nature 
compound via sequential bioconversions54-59. However, it is not easy to find 
and array appropriate multiple biocatalysts to carry out sequential biocatalysis 
with non-natural substance to achieve full conversion. To date, only scarce 
examples have been reported for sequential transformations with tandem 
biocatalysis in organic synthesis. One type of tandem biocatalysis is sequential 
oxidation-reduction for deracemization of secondary alcohol60,61 or !-hydroxy 
acid62 with oxidase and reductase; another one is sequential oxidation-
hydrolysis for asymmetric dihydroxylation of aryl olefins with styrene 







Scheme 5.1 Selective sequential oxidations of methylene group into ketone via tandem 


















Selective oxidation of methylene group (C-H bonds) into ketone is a useful 
synthetic method to generate many crucial chemical and pharmaceutical 
compounds. However, methylene groups, abundant in chemical structures, are 
the most challenging chemical groups to be selectively functionalized, since 
they are inert to most chemical reagents. Although many transition 
metal catalysts (Co, Ru, Cu, Pd, Mn, W,)68-77 and few other catalysts78,79 were 
reported to catalyze selectiveconversion of aryl and allylic secondary C-H into 
C=O, all of them gave a mixture of product with substrate, alcohol,71,78 
acid,71,78 or other ketone byproducts due to the low regioselectivity.70,72-77 
Moreover, those processes also suffered from the use of large amount of 
organic reagent,76,79 toxic metal catalyst,70-76 high temperature,70,71,75,78 
increased pressure,71,78 low conversion75,77,78. Furthermore, it has thus far 
remained impossible to oxidize non-activated C-H into C=O with high 
selectivity.80-83 Some microorganisms were able to transform methylene group 
of non-natural compounds into ketone via secondary. However, the yield and 
activity were low, the reaction time was long, and the product was a mixture 
of alcohol, ketone and unreacted substrate.217-222 Here, we aim to develop 
novel tandem biocatalysis as the first example for selective sequential 
oxidations of methylene group into ketone by the use of a monooxygenase and 
an alcohol dehydrogenase (ADH) in one pot (Scheme 5.1).  The suitable 
biocatalysts for each step were selected from different microorganisms and 
arrayed in an appropriate ratio for efficient tandem catalysis, leading to the 








Tetralin 1a (> 99%), (R)-1-tetralol 2a (> 97%), (S)-1-tetralol 2a (> 97%), 1-
tetralone 3a (> 99%), indan 1b (> 99%), (R)-1-indanol 2b (! 99%), (S)-1-
indanol 2b (! 99%), 1-indanone 3b (! 99%), 1-benzyl-4-hydroxy-piperidine 5 
(96%), 1-benzyl-4-piperidone 6 (99%), ampicillin (> 99%), kanamycin 
solution (50 mg/ml), NAD+ (> 99%), NADH (> 99%), NADP+ (> 99%) and 
NADPH (> 99%) were purchased from Sigma-Aldrich. Isopropyl "-D-
thiogalactopyranoside (ITPG, > 99%) was bought from 1st BASE. Tryptone 
and yeast extract were purchased from Biomed Diagnostics. N-benzyl-
peperidine 4 was prepared according to the published procedures with 59.5% 




LKADH (~0.4 units/mg) was purchased from Sigma-Aldrich. Pseudomonas 
monteilii TA-5,89 E. coli BL21 (DE3) - pRSFDuet P450pyr - pETDuet Fdx 
FdR1500221, and E. coli pET28a histag-RDR161 were obtained from the 







5.2.3 Analytical methods 
 
The concentrations of tetralin 1a , (R)-1-tetralol 2a, (S)-1-tetralol 2a, 1-
tetralone 3a, indan 1b, (R)-1-indanol 2b, (S)-1-indanol 2b, 1-indanone 3b, and 
ee values of 1-tetralol 2a, 1-indanol 2b were analyzed by Shimadzu 
Prominence HPLC on a Chiralcel OB-H column (150 mm " 2.1 mm) at 25 ºC. 
UV detection: 210 nm; eluent:  n-hexane/2-propanol (95:5); flow rate: 1 
ml/min; retention time: 3.8 min for tetralin 1a, 4.1 min for indan 1b, 7.3 min 
for (R)-1-tetralol 2a, 8.6 min for (R)-1-indanol 2b, 11.1 min for (S)-1-tetralol 
2a, 11.7 min for benzyl alcohol, 13.3 min for 1-tetralone 3a, 13.6 min for (S)-
1-indanol 2b, and 20.5 min for 1-indanone 3b.  
The concentrations of N-benzyl-piperidine 4, 1-benzyl-4-hydroxy-piperidine 5 
and 1-benzyl-4-piperidone 6 were analyzed by Shimadzu Prominence HPLC 
on a ZORBAX Eclipse plus C18 column (150 mm " 4.6 mm) at 25 ºC. UV 
detection: 210 nm; eluent: acetonitrile/10 mM KP buffer pH 7.7 (20:80); flow 
rate: 1 ml/min; retention time: 5.8 min for 1-benzyl-4-hydroxy-piperidine 5, 
10.0 min for 1-phenylethanol as internal standard, 18.6 min for N-benzyl-
piperidine 4, and 27.5 min for 1-benzyl-piperidon 6. 
 
5.2.4 Cultivation of microorganisms 
 
Pseudomonas monteilii TA-5 was inoculated on M9 agar plate containing 
trace element, and grown at room temperature for 2 days with toluene vapor as 
carbon source. A single colony from the M9 agar plate was inoculated into 10 
mL of LB medium, and the cells were grown at 300 rpm and 30 ºC for 7 h. 2 
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mL of the above preculture was added in 100 ml M9 medium containing trace 
element in a 250 mL shaking flask with ventilated plastic stopper. 15 mL 
plastic tube with length of 9 cm containing 1 mL toluene was put into the flask, 
and the vapor of toluene was used as carbon source. The mixture was 
incubated at 250 rpm and 30 ºC for 18 h. Then the cells were harvested by 
centrifugation at 10,375 g for 10 min and the cells were directly used for 
biotransformation.89 
E. coli BL21 (DE3) - pRSFDuet P450pyr - pETDuet Fdx FdR1500 was 
inoculated on LB agar plate containing ampicillin (100 #g/mL) and 
kanamycin (50 ug/mL), and grown overnight at 37 ºC. A single colony from 
the LB agar plate was inoculated into 10 mL of LB medium with ampicillin 
(100 #g/mL) and kanamycin (50 ug/mL), and the cells were grown at 300 rpm 
and 37 ºC for 12 h. 2 mL of the above preculture was added in 100 mL LB 
medium containing ampicillin (100 #g/mL) and kanamycin (50 ug/mL), and 
the mixture was shaken at 300 rpm and 37 ºC. IPTG (0.5 mM) was added 
when OD600 reached around 0.8~1.0 at 2 h, and then the mixture was shifted to 
300 rpm, 30 ºC, and shaken for another 3 h. Then the cells were harvested by 
centrifugation at 10,375 g for 10 min and the cells were directly used for 
biotransformation.  
E. coli pET28a histag-RDR was inoculated on LB agar plate containing 
kanamycin (50 ug/mL), and grown overnight at 37 ºC. A single colony from 
the LB agar plate was inoculated into 10 mL of LB medium with kanamycin 
(50 ug/mL), and the cells were grown at 250 rpm and 37 ºC for 12 h. 1 mL of 
the above preculture was added in 100 mL TB medium (12 g Bacto tryptone, 
24 g Bacto yeast extract, 4 mL glycerol, KH2PO4 2.3 g, K2HPO4 12.54 g in 1 
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liter deionized water) containing kanamycin (50 ug/mL), and the mixture was 
shaken at 250 rpm and 37 ºC. IPTG (0.25 mM) was added when OD600 
reached around 0.6~0.8 at 2 h, and then the mixture was shifted to 250 rpm, 25 
ºC, and shaken for another 16~20 h. Then the cells were harvested by 
centrifugation at 10,375 g for 10 min and the cells were directly used for 
biotransformation or enzyme purification.  
 
5.2.5 Purification of histag-RDR 
 
The above freshly harvested E. coli pET28a histag-RDR cells were 
resuspended in 10 mM imidazole buffer to a cell density of 20 g cdw/L, and 
passed through a homogenizer twice (Constant cell disruption system) at 20 
kpsi. The cell debris was removed by centrifugation at 14,000 g for 30 minutes. 
The supernatant (i.e., lysate) was reserved for further purification. The above 
cell lysate was filtrated through 0.2 #M membrane filter. 5 mL (6 g protein/L) 
cell lysate was incubated with 0.5 mL Ni-NTA at 4 ºC for 1 h. The incubated 
mixture was loaded to column and filtrated. Droplets were collected. The 
column was washed with 10 mM (10 mL), 20 mM (10 mL), 30 mM (10 mL), 
50 mM (0.5mL) imidazole buffer; and then eluted with 250 mM imidazole 
buffer 5 " 0.5 mL. All filtrates were separately collected. The protein 
concentration of each fraction was determined by Bradford protein content 
assay170 with bovine serum albumin (BSA) as standard. 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed by loading on a gel containing 0.1% SDS and 12% acrylamide, 
staining the gel with a 0.1% solution of Coomassie brilliant blue R-250 in 
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methanol-acetic acid-water (4:1:5, vol/vol/vol), and destaining the gel by 





Figure 5.1. SDS-PAGE of cell lysate (lane 1); loading filtrate (lane 2); 10 mM imidazole 
buffer wash sample (lane 3); 50 mM imidazole buffer wash sample (lane 4); 250 mM 
imidazole buffer wash fraction one (lane 5); 250 mM imidazole buffer wash fraction two (lane 
6); 250 mM imidazole buffer wash fraction three (lane 7); 250 mM imidazole buffer wash 
fraction four (lane 8); 250 mM imidazole buffer wash fraction five (lane 9). 
 
The five fractions of 250 mM imidazole buffer wash were collect together, 
exchanged with potassium phosphate (KP) buffer (100 mM; pH = 8.0), and 
directly used for biotransformation.  
 
5.2.6 Selective hydroxylation of tetralin 1a and indan 1b with P. monteilli 
TA-5 
 
To 990 #l 1.5 g/L P. monteilii TA-5 cell suspension in Tris-HCl buffer (100 
mM; pH = 7.0) was added 2 mM (10 #l 0.2 M stock solution in methanol) 1a. 
The mixture was shaken at 1000 rpm and 30 ºC for 15 min on benchtop 





















was added and mixed. The organic phase was separated after centrifugation, 
dried over anhydrous Na2SO4, and followed by the analysis of normal phase 
HPLC. 
To 990 #l 1.5 g/L P. monteilii TA-5 cell suspension in Tris-HCl buffer (100 
mM; pH = 7.0) was added 2 mM (10 #l 0.2 M stock solution in methanol) 1b. 
The mixture was shaken at 1000 rpm and 30 ºC for 15 min on benchtop 
thermomixer. At 15 min, 1 mL ethyl acetate containing 1 mM benzyl alcohol 
was added and mixed. The organic phase was separated after centrifugation, 
dried over anhydrous Na2SO4, and followed by the analysis of normal phase 
HPLC. 
 
5.2.7 Oxidation of (R)-1-tetralin 2a and (R)-1-indan 2b with LKADH 
 
To 980 #l Tris-HCl buffer (100 mM; pH = 7.0) was added 4 mM (R)-2a, 4 
mM (20 #l 0.2 M stock solution in deionized water) NADP+ and 2 mg 
LKADH. The mixture was shaken at 1000 rpm and 30 ºC for 15 min on 
benchtop thermomixer. At 15 min, 1 mL ethyl acetate containing 1 mM benzyl 
alcohol was added and mixed. The organic phase was separated after 
centrifugation, dried over anhydrous Na2SO4, and followed by the analysis of 
normal phase HPLC. 
To 980 #l Tris-HCl buffer (100 mM; pH = 7.0) was added 4 mM (R)-2b, 4 
mM (20 #l 0.2 M stock solution in deionized water) NADP+ and 2 mg 
LKADH. The mixture was shaken at 1000 rpm and 30 ºC for 15 min on 
benchtop thermomixer. At 15 min, 1 mL ethyl acetate containing 1 mM benzyl 
alcohol was added and mixed. The organic phase was separated after 
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centrifugation, dried over anhydrous Na2SO4, and followed by the analysis of 
normal phase HPLC. 
 
5.2.8 Reduction of acetone to iso-propanol with NADPH as cofactor 
 
To 2.975 mL Tris-HCl buffer (100 mM; pH = 7.0) was added 10 mM acetone, 
1 mM (15 #l 0.2 M stock solution in deionized water) NADPH, and 1 mg 
LKADH. The decrease of NADH was monitored by determining the UV 
absorption at 340 nm at 30 °C, and the concentration was calculated by using a 
$340 of 6.22 liters mmol-1. The specific activity was expressed in units/g 
protein, and 1 U was defined as the decrease of 1 #mol NADPH/min. 
 
5.2.9 Selective hydroxylation of N-benzyl-piperidine 4 with E. coli 
(P450pyr) 
 
To 950 #l 1.5 g/L cell suspension in KP buffer (100 mM; pH = 8.0) was added 
2% (w/v) glucose (40 #l 50% stock solution) and 2 mM (10 #l 0.2 M stock 
solution in methanol) 4. The mixtures were shaken at 1000 rpm and 30 ºC for 
15 min on benchtop thermomixer. At 15 min, 1 mL methanol with 2 mM 1-
phenylethanol was added, mixed, centrifuged, and the supernatant was taken 
and analyzed by reverse phase HPLC. 
 
5.2.10 Oxidation of 1-benzyl-4-hydroxy-piperidine 5 with RDR 
 
To 980 #l 0.2 g protein/L solution in KP buffer (100 mM; pH = 8.0) was 
added 2 mM (10 #l 0.2 M stock solution in methanol) 5 and 2 mM (10 #l 0.2 
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M stock solution in deionized water) NAD+. The mixtures were shaken at 
1000 rpm and 30 ºC for 15 min on benchtop thermomixer. At 15 min, 1 mL 
methanol with 2 mM 1-phenylethanol was added, mixed, centrifuged, and the 
supernatant was taken and analyzed by reverse phase HPLC. 
 
5.2.11 Reduction of acetone to iso-propanol with NADH as cofactor 
 
To 2.975 mL 0.2 g protein/L solution in KP buffer (100 mM; pH = 8.0) was 
added 10 mM acetone, and 1 mM (15 #l 0.2 M stock solution in deionized 
water) NADH. The decrease of NADH was monitored by determining the UV 
absorption at 340 nm at 30 °C, and the concentration was calculated by using a 
$340 of 6.22 liters mmol-1. The specific activity was expressed in units/g 
protein, and 1 U was defined as the decrease of 1 #mol NADH/min. 
 
5.2.12 Typical procedure for selective sequential oxidations of tetralin 1a 
to 1-tetralone 3a via tandem biocatalysis with NADP+ recycling in one pot  
 
To 5 mL P. monteilii TA-5 cell suspension (10 g cdw/L) in Tris-HCl buffer 
(100 mM; pH 7.0) was added 3 g protein/L (15 mg) LKADH, 0.002 mM 
NADP+ (5 #l 0.002 M stock solution), 0.5% (v/v, 25 #l) acetone, 1 mM MgCl2 
(50 #l 0.1 M stock solution), and 6 mM (4.0 mg, 0.03 mmol) tetralin 1a. The 
mixture was shaken at 250 rpm and 30 ºC. At 2 h, cell pellets (24 mg cdw) of 
P. monteilii TA-5 were directly added to reaction system. Aliquots (100 #l) 
were taken out at different time points and mixed with 100 #l ethyl acetate 
containing 1 mM benzyl alcohol as internal standard. The cells were removed 
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by centrifugation, and organic phase was separated and dried over anhydrous 
Na2SO4. The samples were analyzed by normal phase HPLC. 
 
5.2.13 Typical procedure for selective sequential oxidations of tetralin 1a 
and indan 1b to 1-tetralone 3a and 1-indanone 3b via tandem biocatalysis 
with NADP+ recycling in one pot  
 
To 5 mL P. monteilii TA-5 cell suspension (10 g cdw/L) in Tris-HCl buffer 
(100 mM; pH 7.0) was added 3 g protein/L (15 mg) LKADH, 0.002 mM 
NADP+ (5 #l 0.002 M stock solution), 0.5% (v/v, 25 #l) acetone, 1 mM MgCl2 
(50 #l 0.1 M stock solution), and 6 mM (3.9 mg, 0.03 mmol) indan 1b. The 
mixture was shaken at 250 rpm and 30 ºC. At 2 h, cell pellets (24 mg cdw) of 
P. monteilii TA-5 were directly added to reaction system. Aliquots (100 #l) 
were taken out at different time points and mixed with 100 #l ethyl acetate 
containing 1 mM benzyl alcohol as internal standard. The cells were removed 
by centrifugation, and organic phase was separated and dried over anhydrous 
Na2SO4. The samples were analyzed by normal phase HPLC. 
 
5.2.14 Typical procedure for selective sequential oxidations of N-benzyl-
piperidine 4 to 1-benzyl-4-piperidone 6 via tandem biocatalysis with 
NAD+ recycling in one pot  
 
To 5 mL E. coli BL21 (DE3) - pRSFDuet P450pyr - pETDuet Fdx FdR1500 
cell suspension (10 g cdw/L) in KP buffer (100 mM; pH 8.0) was added 4 g 
protein/L purified histag-RDR, 0.002 mM NAD+ (5 #l 0.002 M stock solution), 
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0.5% (v/v, 25 #l) acetone, 0.5 % (w/v, 50 #l 50% stock solution), and 5 mM 
(4.4 mg, 0.025 mmol) N-benzyl-piperidine 4. The mixture was shaken at 250 
rpm and 30 ºC. Aliquots (100 #l) were taken out at different time points and 
mixed with 100 #l methanol containing 2 mM 1-phenylethanol as internal 
standard. The cells were removed by centrifugation. The samples were 
analyzed by reverse phase HPLC. 
 
5.3 Results and Discussion  
 
5.3.1 Tandem biocatalysts system for the selective sequential oxidations of 
tetralin 1a to 1-tetralone 3a with NADP+ recycling 
 
To prove the novel concept of combining a monooxygenase and an ADH for 
tandem oxidations, the transformation of tetralin 1a to 1-tetralone 3a via 1-
tetralol 2a was chosen as model reaction (Scheme 5.2). 1-tetralone 3a is an 
important pharmaceutical intermediate to prepare contraceptive 18-methyl 
norethisterone, antidepressant sertaline, and insecticide carboryl.223,224 All 
reported syntheses of 1-tetralone 3a from tetralin 1a resulted in a mixture of 
3a together with 2a, 1a, 2-tetralone,225 1,4-naphthaquinone,226 1-naphthol,227 
naphtahalene227. Moreover, those methods involved the use of large amount of 
organic reagent,227-229 toxic metal catalyst,221,226,227,230-232 high pressure,221,230 
and gave low conversion225,231. Several microorganisms were also reported to 
catalyze the conversion of tetralin 1a into 1-tetralone 3a, but with a mixture of 
products in low concentration.155,233,234 In our study, the whole cell of 
Pseudomonas monteilii TA-5 was chosen as the first-step biocatalyst, since it 
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could selectively hydroxylate tetralin 1a at benzylic position to (R)-1-tetralol 
with 60% yield and 99% ee.89 The commercially available Lactobacillus kefir 
alcohol dehydrogenase (LKADH) was selected as the second-step biocatalyst, 
since it is a versatile ADH accepting a broad variety of substrates.235,236 
Meanwhile, excess amount of acetone was supplied as “coupled 
substrate”8,9,119,123 to  regenerate the expensive cofactor NADP+, in order to 






Scheme 5.2 Selective sequential oxidations of benzylic C-H into C=O via tandem biocatalysis 
with NADP+ recycling in one pot.  
 
The activity of biocatalyst for each step reactions in the whole tandem 
biocatalysis was tested at the beginning. Freshly harvested whole cells of P. 
monteilii TA-5 showed an activity of 12 U/g cdw to hydroxylate tetralin 1a to 
(R)-2a with 99% regioselectivity. While LKADH oxidized (R)-1-tetralol 2a to 
1-tetralone 3a with an activity of 4.5 U/g protein, it also reduced acetone to 
iso-propanol with a much higher activity (250 U/g protein), thus being 
beneficial to NADP+ recycling. Possible side reactions were also examined. P. 
monteilii TA-5 cells oxidized (R)-2a to 3a with an activity of 0.41 U/g cdw, 
possibly due to the existence of dehydrogenase in the whole cell. This activity 
is very low compared to that of LKADH. Like most ADH, LKADH also 
reduced ketone 3a to alcohol 2a with an activity of 0.80 U/g protein, which is 






















successfully annihilated by adding excess amount of acetone (0.5% v/v). We 
also found that LKADH lost oxidative activity easily in Tris-HCl buffer, and 1 















Figure 5.2. Selective sequential oxidations of tetralin 1a to 1-tetralone 3a via tandem 
biocatalysis with NADP+ recycling in one pot. A: 1-tetralone 3a standard, BA is internal 
standard benzyl alcohol; B: 1 h sample; C: 5 h sample; D: 30 h sample. Reaction conditions: 6 
mM 1a, 10+5 g cdw/L TA-5, 3.5 g protein/L LKADH, and 0.001 mM NADP+. 
 
In the initial explorative experiments of selective sequential oxidation-
oxidation, the reaction was performed with 10 g cdw/L of P. monteilii TA-5, 2 
g protein/L of LKADH, 6 mM tetralin 1a, 0.002 mM NADP+ and 0.5% (v/v) 
acetone in 5 ml Tris-HCl buffer (Table 5.1, entry 2). Compared to the control 
reaction (Table 5.1, entry 1), much more 1-tetralone 3a was produced within 
















Table 5.1. Selective sequential oxidations of tetralin 1a and indan 1b to 1-tetralone 3a and 1-
























1 1a 10 - - - 0.80 2.76 1.72 > 99 13 - 
2 1a 10 2 0.002 0.5 3.46 0.12 1.76 > 99 58 1300 
3 1a 10   2e 
  
0.002e 
  0.5e 3.00 0.25 1.65 > 99 50 1100 
4 1a 10+5f - - - 0.92 3.92 0.36 > 99 15 - 
5 1a 10+5f 2 0.002 0.5 5.06 0.16 0 > 99 84 2100 
6 1a 10+5f 3 0.002 0.5 5.25 0 0 > 99 88 2200 
7 1a 10+5f 2 0.002 0.5+0.5 +0.5g 5.12 0.15 0 > 99 85 2100 
8 1a 10+5f 2 0.001 0.5 4.07 0.53 0 > 99 68 3200 
9 1a 10+5f 3 0.001 0.5 4.75 0.20 0 > 99 79 3800 
10 1a 10+5f 3.5 0.001 0.5 4.98 0 0 > 99 83 4100 
11 1b 10+5f - - - 0.98 4.32 0 > 99 16 - 
12 1b 10+5f 3 0.002 0.5 5.41 0 0 > 99 90 2200 
13 1b 10+5f 3.5 0.001 0.5 5.20 0 0 > 99 87 4200 
a) All reactions were carried out with 6 mM 1 in Tris-HCl (100 mM, pH = 7.0) buffer 
containing 1 mM MgCl2 at 30 ºC and 250 rpm.  
b) Concentrations of different compounds in the reaction mixture at 30 h.  
c) The regioselectivity is referred to the ratio between 1-tetralone 3a to 2-tetralone or the ratio 
between 1-indanone 3b to 2-indanone.  
d) The concentration of 3 produced by TA-5 cells alone in control reaction (entry 1, 4 and 11) 
was deducted in the calculation of TTN.  
e) LKADH, NADP+ and acetone were added at 2 h instead of at the beginning.  
f) Additional TA-5 cell pellets were added at 2 h to increase the cell density to 15 g/L.  
g) Additional acetone was added at 7 h and 20 h, respectively. 
 
However, there was still certain amount of 1a and (R)-2a left. Adding 
LKADH, NADP+ and acetone at later stage did not help to improve the whole 
conversion (Table 5.1, entry 3). In fact, P. monteilii TA-5 only showed high 
hydroxylation activity at the first two hours, and the activity dropped quickly 
afterwards. In order to fully convert 1a to 3a, more P. monteilii TA-5 was 
added at 2 h which increased the final concentration of 3a to 5.06 mM (Table 
5.1, entry 5). Increasing LKADH to 3 g/L gave rise to complete conversion. 
At 30 h, pure 3a was produced in 5.25 mM with 87.5% yield, 99% 
regioselectivity, and a TTNof 2200 for NADP+ recycling (Table 5.1, entry 6). 
To increase TTN, 0.001 mM NADP+ was used to carry out the 
biotransformation (Table 5.1, entries 8 to 10).  As shown in Figure 5.3, when 
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3.5 g/L LKADH was used, the accumulative concentration of 2a reached 
maximum at 3 h, and the concentration of 3a increased very fast in the first 20 
h. At 30 h, pure 3a was produced in 4.98 mM with 83.0% yield, 99% 
regioselectivity, and a TTN of 4100 for NADP+ recycling (Table 5.1, entry 10). 
Such high TTN meets the widely accepted cofactor recycling criteria for 
practical application. This is the first example of utilizing tandem biocatalyst 
system for selective sequential oxidations with cofactor recycling.  
 
5.3.2 Tandem biocatalysts system for the selective sequential oxidations of 
indan 1b to 1-indanone 3b with NADP+ recycling 
 
Indan 1b with similar chemical structure to tetralin 1a was also examined for 
the same sequential oxidations (Scheme 5.2). The desired product 1-indanone 
3b is an important intermediate in the synthesis of serotonin reuptake 
inhibitors.237 P.monteilii TA-5 hydroxylated indan 1b to (R)-1-indanol 2b with 









Figure 5.3. Time course of selective sequential oxidations of tetralin 1a and indan 1b to 1-
tetralone 3a and 1-indanone 3b via tandem biocatalysis with NADP+ recycling in one pot. 3a 
(%), (R)-2a (△), 3b (&) and (R)-2b ('). Reaction conditions: 6 mM 1a or 1b, 10+5 g cdw/L 




























Figure 5.4. Selective sequential oxidations of indan 1b to 1-indanone 3b via tandem 
biocatalysis with NADP+ recycling in one pot. A: 1-tetralone 3b standard, BA is internal 
standard benzyl alcohol; B: 1 h sample; C: 5 h sample; D: 30 h sample. Reaction conditions: 6 
mM 1b, 10+5 g cdw/L TA-5, 3.5 g protein/L LKADH, and 0.001 mM NADP+. 
 
2b to 1-indanone 3b with an activity of 3.5 U/g protein, and could not reduce 
3b back to 2b in the presence of excess amount of acetone. Tandem catalyses 
were carried out in the similar conditions to using tetralin 1a as substrate 
(Table 5.1, entries 11 to 13). By coupling P. monteilii TA-5 with LKADH, 
much more 3b was produced than using P. monteilii TA-5 alone. Initially 
adding 0.002 mM NADP+ led to the preparation of 5.41 mM 3b at 30 h, with 
90.2% yield, 99% regioselectivity, and a TTN of 2200 for NADP+ recycling. 
When lowering the initial NADP+ concentration to 0.001 mM and increasing 











5.3.3 Tandem biocatalysts system for the selective sequential oxidations of 







Scheme 5.3 Selective sequential oxidations of non-activated C-H into C=O via tandem 
biocatalysis with NAD+ recycling in one pot.  
 
The novel concept of utilizing tandem biocatalysis for selective sequential 
oxidations with cofactor recycling was also proved by sequential oxidation-
oxidation of N-benzyl-piperidine 4 to 1-benzyl-4-piperidone 6 via 1-benzyl-4-
hydroxy-piperidine 5 with two different biocatalysts (Scheme 5.3). The target 
compound 6 is an important intermediate for the production of drugs for the 
treatment of asthma, hypertension or depression.238 So far, 6 is mainly 
produced from phenylmethanamine and acrylic acid methyl ester through  
multi-step reactions with low yield.239 In our study, E. coli BL21 (DE3) - 
pRSFDuet P450pyr - pETDuet Fdx FdR1500 [E. coli (P450pyr)] was chosen as 
the first-step biocatalyst, since the P450pyr was known to selectively 
hydroxylate the non-active carbon atom of 4 at 4-position.68 E. coli pET28a 
histag-RDR [E. coli (RDR)] was selected as the second-step biocatalyst, since 
the RDR could catalyze the conversion between hydroxypiperidine and 
piperidone.240 At the beginning, we used the whole cells of the two 
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intracellular cofactor by adding 0.5% (v/v) acetone and 0.5% (w/v) glucose. 
However, 1-benzyl-4-piperidone 6 was obtained at low concentration.  
 
Table 5.2. Selective sequential oxidations of N-benzyl-piperidine 4 to 1-benzyl-4-piperidone 6 
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 [mM] 
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 [mM] 







1 5 - - - 0 4.52 0 >99 0 - 
2 5 4 0.002 0.5 3.61 0.12 0.72 >99 72 1800 
3 10 4 0.002 0.5 4.28 0 0 >99 86 2100 
4 10 4 0.001 0.5 4.02 0 0 >99 80 4000 
a) All reactions were carried out with 5 mM 4 in KP (100 mM, pH = 8.0) buffer containing 
0.5 % (w/v) glucose at 30 ºC and 250 rpm.  
b) Concentrations of different compounds in the reaction mixture at 25 h.  
c) The regioselectivity is referred to the ratio between 1-benzyl-4-piperidone 6 to 1-benzyl-3-
piperidone or 1-benzyl-2-piperidone. 
d) The concentration of 6 produced by P450pyr cells alone in control reaction (entry 1) was 














Figure 5.5. Selective sequential oxidations of N-benzyl-piperidine 4 to 1-benzyl-4-piperidone 
6 via tandem biocatalysis with NAD+ recycling in one pot. A: 1-benzyl-4-piperidone 6, PA is 
internal standard 1-phenylethanol; B: 1 h sample; C: 5 h sample; D: 25 h sample. Reaction 












Further study found that E. coli (RDR) lost its oxidative activity from 5 to 6 in 
the presence of trace amount of glucose. There might be glucose 
dehydrogenase in the cells which also consumes cofactor NAD+, thus 
inhibiting the oxidation of 5 to 6. This problem was solved by using purified 
histag-RDR as biocatalyst. Purified histag-RDR oxidized 5 to 6 at an activity 
of 54 U/g protein, while reducing acetone to iso-propanol at an activity of 480 
U/g protein for NAD+ recycling. In the presence of 0.5% (v/v) of acetone, the 
activity of purified histag-RDR for reducing 6 to 5 was also inhibited. E. coli 
(P450pyr) hydroxylated N-benzyl-piperidine 4 with an activity of 8.0 U/g cdw, 
and was not able to further oxidize 1-benzyl-4-hydroxy-piperidine 5 to 1-
benzyl-4-piperidone 6. Sequential catalyses were carried out in the similar 
ways as above. At the beginning, 5 g/L cdw of E. coli (P450pyr) was coupled 
with 4 g protein/L of purified histag-RDR (Table 5.2, entry 2). However, 
compared with control reaction (Table 5.2, entry 1), the conversion of 4 only 
reached 85%, which means that purified histag-RDR influenced the 
hydroxylation activity. 10 g/L of E. coli (P450pyr) were then used. Initially 
adding 0.002 mM NAD+ led to the formation of 4.28 mM 6 at 25 h, with 
85.6% yield, 99% regioselectivity, and a TTN of 2100 for NAD+ recycling. 
When lowering the initial NAD+ concentration to 0.001 mM, final TTN 







5.4 Summary and Conclusions 
 
Herein, we have demonstrated the first examples of selective sequential 
oxidations of methylene group into ketone via tandem biocatalysis with 
cofactor recycling in one pot. In one case, valuable ketones were prepared via 
selective oxidation-oxidation of hydrocarbon at benzylic position with NADP+ 
recycling with monooxygenase containing wild-type strain and LKADH; in 
the other case, useful ketone were prepared through selective oxidation-
oxidation of non-activated C-H into C=O with NAD+ recycling by the use of 
recombinant strain expressing P450pyr monooxygenase and RDR. While this 
type of transformation is still extremely challenging in classical chemistry, the 
use of tandem biocatalysis enables the efficient sequential oxidations and 
gives the desired ketones in pure form with high yield, high regioselectivity 
and high TTN for cofactor recycling. The strategy demonstrated here is also 
generally applicable to other sequential oxidations of methylene group into 








































In this thesis, several novel and efficient biocatalytic systems for 
oxidoreductions in pharmaceutical synthesis was developed, including 
bioreduction with efficient recycling of NADPH by coupled permeabilized 
microorganisms, regio- and stereo-selective biohydroxylations with a 
recombinant Escherichia coli expressing P450pyr monooxygenase of 
Sphingomonas sp. HXN-200, and the green and selective transformation of 
methylene to ketone via tandem biooxidations in one pot. 
Firstly, a novel and efficient biocatalytic system for bioreduction with efficient 
recycling of NADPH was successfully developed by the coupling of two 
permeabilized microorganisms. The method is a useful extension of our 
previous novel concept for efficient bioreduction with cofactor recycling by 
two coupled permeabilized microorganisms. In the original approach, the TTN 
for cofactor recycling and final product concentration were not high enough 
for practical application, due to the relative low activity of the cofactor 
recycling biocatalyst. Here, a recombinant strain was constructed to improve 
the activity of the cofactor recycling. The GDH of B. subtilis BGSC 1A1 was 
cloned and functionally expressed in E. coli BL21 (pGDH1), showing an 
activity much higher than its wild-type strain B. subtilis BGSC 1A1. The 
recombinant strain was successfully permeabilized with EDTA/toluene to give 
a high activity for cofactor recycling. Such permeabilized cells demonstrated 
much higher GDH activity and no NADPH or NADH oxidase activity, being 
advantageous over the wild-type strain. They were suitable for the recycling of 
both NADPH and NADH. Coupling of permeabilized cells of B. pumilus Phe-
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C3 and E. coli BL21 (pGDH1) for the reduction of ethyl 3-keto-4-
triflurobutyrate 1 gave a TTN of 4200 for NADPH recycling, which  is 2.6 
times of the TTN obtained by using B. subtilis BGSC 1A1. The high TTN 
value is in the practical range for the synthesis of fine chemicals. Bioreduction 
of 3-ketoester via coupled permeabilized cells with the addition of 0.005 mM 
NADP+ for 3 times gave 50.5 mM of 3-hydroxyester in 95% ee and 84% 
conversion with an overall TTN of 3400 for NADPH recycling. These results 
demonstrated the high stability and productivity of the new biocatalysts 
system and a practical synthesis of (R)-ethyl 3-hydroxy-4-trifluorobutanoate. 
Our method could be applicable to other microbial reductions with cofactor 
recycling.  
Secondly, a recombinant Escherichia coli expressing P450pyr monooxygenase 
of Sphingomonas sp. HXN-200 was successfully constructed with high 
activity and applied for regio- and stereo-selective biohydroxylations of 
different type of substrates. The genes of cytochrome P450pyr from 
Sphingomonas sp. HXN-200 were cloned and functionally expressed in the E. 
coli BL21 - pRSFDuet P450pyr - pETDuet Fdx FdR1500, and the specific 
hydroxylation very close to those achieved with its wild-type strain. The 
recombinant P450pyr represents the high specific hydroxylation activities 
among all the recombinant P450 reported so far. 10.8 mM (S)-N-benzyl-4-
hydroxy-pyrrolidin-2-one was obtained under the optimized biohydroxylation 
conditions, a 2.6-fold increase of the product concentration in comparison with 
the wild-type strain. This recombinant E. coli was the only strain reported to 
produce exo-norbornaneol, 2-tetralol and 7-methoxy-2-tetralol through direct 
biohydroxylation of the non-activated carbon atoms of their corresponding 
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substrates. It also gave the most practical biohydroxylation example to 
produce (1R)-trans-pinocarveol with high conversion and product 
concentration. The hydroxylation of (-)-!-pinene with E. coli (P450pyr) cells 
showed excellent regio- and stereo-selectivity and gave (1R)- trans-
pinocarveol in 82% yield and 4.1 mM, being over 200 times higher than that 
obtained with the best biocatalysts known thus far. 
Lastly, the first practical examples of selective sequential oxidations of 
methylene group into ketone via tandem biocatalysis with cofactor recycling 
in one pot were demonstrated. Valuable 1-tetralone and 1-indanone were 
prepared via selective oxidation-oxidation of tetralin and indan at benzylic 
position with NADP+ recycling by coupling whole-cell biocatalyst P. monteilii 
TA-5 containing monooxygenase with a commercially available enzyme 
Lactobacillus kefir alcohol dehydrogenase (LKADH). With the initial addition 
of 0.002 mM NADP+, pure 1-tetralone was produced in 5.25 mM with 87.5% 
yield, 99% regioselectivity, and a TTN of 2200 for NADP+ recycling; pure 1-
indanone was produced in 5.41 mM with 90.2% yield, 99% regioselectivity, 
and a TTN of 2200 for NADP+ recycling. By lowering initial amount of 
NADP+ to 0.001 mM and adding appropriate amount LKADH, 1-tetralone and 
1-indanone were also directly produced from tetralin and indan through clean 
tandem catalysis, and with increased TTN of 4100 and 4200, respectively. 
Useful 1-benzyl-4-piperidone was prepared through selective oxidation-
oxidation of non-activated C-H into C=O with NAD+ recycling by the use of 
recombinant strain expressing P450pyr monooxygenase and RDR. While this 
type of transformation is still extremely challenging in classical chemistry, the 
use of tandem biocatalysis enables the efficient sequential oxidations and 
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gives the desired ketones in pure form with high yield, high regioselectivity 
and high TTN for cofactor recycling. Initial addition of 0.002 mM NAD+ led 
to the formation of 4.28 mM 1-benzyl-4-piperidone at 25 h, with 85.6% yield, 
99% regioselectivity, and a TTN of 2100 for NAD+ recycling. When lowering 
the initial NAD+ amount to 0.001 mM, final TTN was increased to 4000. The 
strategy demonstrated here is also generally applicable to other sequential 
oxidations of methylene group into ketone by selecting and combining the 




The further development of novel and efficient biocatalytic systems for 
oxidoreductions in pharmaceutical synthesis may focus on the following 
aspects. 
The application of permeabilized cells for efficient cofactor recycling is a 
totally novel and promising method. We have successfully coupled two 
permeabilized microorganisms for efficient bioreduction of ethyl 3-keto-4-
triflurobutyrate with cofactor recycling. For the future work, our established 
system may apply to other substrates, and general application. Moreover, we 
can also apply the coupled permeabilized microbial cells concept for 
enzymatic oxidations with cofactor recycling, which is much more challenging 
than bioreductions. For example, cells of E. coli BL21 - pRSFDuet P450pyr - 
pETDuet Fdx FdR1500 containing cytochrome P450pyr could be 
permeabilized by chemical incubation or other permeabilization method, and 
then coupled with permeabilized cells of E. coli BL21 (pGDH1). Such novel 
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system could be used for the efficient biooxidation with cofactor recycling, 
and all the compounds previously explored for E. coli (P450pyr) 
biohydroxyation will be good substrate candidate, such as N-benzyl 
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NAD(P)H NAD(P)+








Scheme 6.1 Coupling of permeabilized microorganisms for efficient enantioselective 
hydroxylation with cofactor recycling. 
 
We have demonstrated the first practical examples of selective sequential 
oxidations of methylene group into ketone via tandem biocatalysis with 
cofactor recycling in one pot, which is a key challenge in traditional chemistry. 
To enhance the performance of our current tandem biocatalysts systems, we 
could construct recombinant cells of our current wild-type stains to improved 
the whole cell activity, and even can utilize directed evolution to further 
improve enzyme activity and stability. For example, in the tandem catalysis of 
tetralin and indan into 1-tetralone and 1-indanone, P. monteilii TA-5 
containing monooxygenase was wide-type strain, which was shown to be the 
limiting factor to achieve better productivity. If we can identify, characterize 
the monooxygenase enzyme in the wild type strain, and engineer and express 
it in E. coli with increased activity and stability, then the performance of the 











can explore other kinds of biocatalysis combination, such as selective 
oxidation from alkane to alcohol, then to aldehyde, which is also very 















Scheme 6.2 Selective sequential oxidations of methyl group into aldehyde via tandem 









Scheme 6.3 Engineering of two enzymes into one host cell for efficient biohydroxylaiton with 
cofactor recycling.  
 
Another possible way to develop tandem biocatalysts system for efficient 
oxidoreductions is to engineer two enzymes necessary for the tandem 
biocatalysis into one host cell, and tune the expression ratio of the two 
enzymes according to the needs of the tandem biocatalysis. For instance, we 
can engineer and express P450pyr monooxygenase and glucose dehydrogenase 
(GDH) in one E. coli host cell for efficient biohydroxylation with practical 
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cofactor recycling (Scheme 6.3). The recombinant microorganism co-
expressing two necessary enzymes might be more convenient and efficient for 
tandem catalysis, but it is very difficult to achieve this point.   
We could also immobilize necessary enzymes onto one or separate carriers for 
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